var title_f3_22_3424="Microarray analysis strategy";
var content_f3_22_3424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F71360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F71360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Analysis strategy for oligonucleotide arrays (microarrays)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 623px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_22_3424=[""].join("\n");
var outline_f3_22_3424=null;
var title_f3_22_3425="Roux stasis syndrome after gastric bypass";
var content_f3_22_3425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Roux stasis syndrome after gastric bypass",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 431px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Roux stasis syndrome with contrast held up in the Roux limb.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_22_3425=[""].join("\n");
var outline_f3_22_3425=null;
var title_f3_22_3426="Arteriovenous malformation CT";
var content_f3_22_3426=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary arteriovenous malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 343px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arteriovenous malformation presenting as a solitary pulmonary nodule in the periphery of the right middle lobe (arrow). Note the proximal tail-like extension corresponding to the supplying artery and the draining vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_22_3426=[""].join("\n");
var outline_f3_22_3426=null;
var title_f3_22_3427="Sore throat in children";
var content_f3_22_3427=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Sore throat in children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/22/3427/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3427/contributors\" id=\"au6229\">",
"       Ellen R Wald, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/22/3427/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3427/contributors\" id=\"se4583\">",
"       Morven S Edwards, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?3/22/3427/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3427/contributors\" id=\"de5754\">",
"       Mary M Torchia, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?3/22/3427?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      SORE THROAT OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Sore throat is a common problem during childhood, and is usually the result of a bacterial or viral infection. Although sore throat usually resolves without complications, it sometimes requires treatment with an antibiotic. There are some less common causes of sore throat that are serious or even life-threatening.",
"    </p>",
"    <p>",
"     This topic will discuss the most common causes and treatments of sore throat in children, as well as the warning signs of more serious conditions. Strep throat in adults is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36082?source=see_link\">",
"      \"Patient information: Sore throat in adults (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      SORE THROAT CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The most likely cause of a child's sore throat depends upon the child's age, the season, and the geographic area. While viruses are the most common cause of sore throat, bacteria are another common cause. Bacteria and viruses are spread from one person to another through hand contact. Hands get contaminated when the sick individual touches their nose or mouth and then touches another person directly (hand-to-hand contact) or indirectly (hand-to-object, such as doorknob, telephone, toys).",
"    </p>",
"    <p>",
"     It is difficult to determine the cause of sore throat based upon symptoms alone; an examination and laboratory test are recommended in most cases. (See",
"     <a class=\"local\" href=\"#H8\">",
"      'Sore throat diagnosis'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Viruses",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are many viruses that can cause pain and swelling of the throat. The most common include viruses that cause sore throat as part of an upper respiratory infection, such as the common cold. Other viruses that cause sore throat include influenza, adenovirus, and Epstein-Barr virus (the cause of mononucleosis).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h3\">",
"      Symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Symptoms that may occur with a viral infection can include a runny nose and congestion, irritation or redness of the eyes, cough, hoarseness, soreness in the roof of the mouth, a skin rash, or diarrhea. In addition, children with viral infections may have a fever and may feel miserable. A high fever does not necessarily mean that the child has a bacterial infection.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Group A streptococcus",
"     </span>",
"     &nbsp;&mdash;&nbsp;Group A streptococcus (GAS) is the name of the bacterium that causes strep throat. Although other bacteria can cause a sore throat, GAS is the most common bacterial cause; up to 30 percent of children with a sore throat will have GAS. Strep throat usually occurs during the winter and early spring, and is most common in school-age children and their younger siblings.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Symptoms of strep throat in children older than three years often develop suddenly and include fever (temperature &ge;100.4&ordm;F or 38&ordm;C), headache, abdominal pain, nausea, and vomiting. Other symptoms can include swollen glands in the neck, white patches of pus in the back or sides of the throat, small red spots on the roof of the mouth, and swelling of the uvula (",
"     <a class=\"graphic graphic_figure graphicRef78761 \" href=\"UTD.htm?8/28/8641\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     A cough and cold are not commonly seen in children over age five years with strep throat.",
"    </p>",
"    <p>",
"     Strep throat is uncommon in children younger than age two to three years. However, GAS infection can occur in younger children, and may cause a runny nose and congestion that is prolonged, low-grade fever (&le;101&ordm;F or 38.3&ordm;C), and tender glands in the neck. Infants younger than one year may be fussy and have a decreased appetite and low-grade fever.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Other causes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other common causes of sore throat that are not related to infection include breathing dry air through the mouth (especially during the winter) and allergies (allergic rhinitis). A small percentage of young children with a sore throat may have a foreign body (eg, toy, coin, food) stuck in the throat, esophagus, or respiratory tract.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      SORE THROAT DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Most cases of sore throat are caused by viruses and do not require treatment. However, it is important to recognize and treat children with strep throat to prevent the spread of infection and also to prevent potentially serious complications of group A streptococcus (GAS) (eg, rheumatic fever).",
"    </p>",
"    <p>",
"     It is difficult for a parent to know whether their child's sore throat is caused by GAS or a virus. Parents are encouraged to call their child's healthcare provider to determine if the child needs to be examined, especially if one or more of the following is present:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Temperature is &ge;101&ordm;F or 38.3&ordm;C",
"      </li>",
"      <li>",
"       Season is late fall, winter, or early spring",
"      </li>",
"      <li>",
"       The child does not have a cough",
"      </li>",
"      <li>",
"       Child's age is between 5 and 15 years",
"      </li>",
"      <li>",
"       Recent exposure to someone with strep throat",
"      </li>",
"      <li>",
"       Difficulty breathing or swallowing",
"      </li>",
"      <li>",
"       Child's voice sounds muffled",
"      </li>",
"      <li>",
"       Stiff neck or difficulty opening the mouth",
"      </li>",
"      <li>",
"       Parent has questions or concerns about child's symptoms",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Laboratory testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;If the provider suspects that the child could have strep throat, a test may be done to confirm the diagnosis. If the child does not have signs or symptoms of strep throat, testing is not usually necessary.",
"    </p>",
"    <p>",
"     There are two types of tests available to diagnose strep throat: a rapid test and a culture. Both tests require the provider to swab the back and sides of the child's throat.",
"    </p>",
"    <p>",
"     Results of the rapid test are available quickly, within a few minutes. Results of the culture are not available for 24 to 48 hours. The best test depends upon the individual child's situation and how quickly results are needed.",
"    </p>",
"    <p>",
"     When the rapid test is used and is negative, a throat culture must be done to confirm that GAS is not present. If the rapid test or culture is positive for GAS, the child will be treated with an antibiotic. (See",
"     <a class=\"local\" href=\"#H11\">",
"      'Strep throat'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      SORE THROAT TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of sore throat depends upon the cause; strep throat is treated with an antibiotic while viral pharyngitis is treated with rest, pain relievers, and other measures to reduce symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Strep throat",
"     </span>",
"     &nbsp;&mdash;&nbsp;Strep throat is usually treated with an antibiotic, such as penicillin, or an antibiotic similar to penicillin (eg, amoxicillin). Children who are allergic to penicillin will be given an alternate antibiotic. The antibiotic is usually given in pill or liquid form two or three times per day. A one-time injection is also available, and may be recommended if a child is unwilling to take an oral medication.",
"    </p>",
"    <p>",
"     After completing 24 hours of antibiotics, the child is no longer contagious and may return to school. Symptoms usually improve within one to two days. However, it is important for the child to finish the entire course of treatment (usually 10 days). If a child does not begin to improve or worsens within three days, the child should be reevaluated.",
"    </p>",
"    <p>",
"     Throat pain can be treated with a non-prescription pain medication, if needed. (See",
"     <a class=\"local\" href=\"#H13\">",
"      'Pain medications'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     In addition, parents should monitor their child for dehydration, which can develop if the child is not willing to drink or eat due to a sore throat. (See",
"     <a class=\"local\" href=\"#H14\">",
"      'Monitor for dehydration'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Viral throat pain",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sore throat caused by viral infections usually last four to five days. During this time, treatments to reduce pain may be helpful but will not help to eliminate the virus. Antibiotics do not improve throat pain caused by a virus and are not recommended.",
"    </p>",
"    <p>",
"     A child with a viral infection is usually allowed to return to school when there has been no fever for 24 hours and the child feels well enough to pay attention.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h3\">",
"      Pain medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Throat pain can be treated with a mild pain reliever such as acetaminophen (sample brand name: Tylenol&reg;) or a non-steroidal anti-inflammatory agent such as ibuprofen (sample brand names: Advil&reg;, Motrin&reg;). These medications should be dosed according to weight, not age.",
"    </p>",
"    <p>",
"     Aspirin is not recommended for children &lt;18 years due to the risk of a potentially serious condition known as Reye syndrome.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Monitor for dehydration",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some children with a sore throat are reluctant to drink or eat due to pain. Drinking less fluid can lead to dehydration. To reduce the risk of dehydration, parents can offer warm or cold liquids. (See",
"     <a class=\"local\" href=\"#H18\">",
"      'Other interventions'",
"     </a>",
"     below.)",
"    </p>",
"    <p>",
"     Signs and symptoms of mild dehydration include a slightly dry mouth, increased thirst, and decreased urine output (one wet diaper or void in six hours). Signs of moderate or severe dehydration include decreased urine output (less than one wet diaper or void in six hours), lack of tears when crying, dry mouth, and sunken eyes.",
"    </p>",
"    <p>",
"     A child who is moderately or severely dehydrated should be evaluated by a healthcare provider as soon as possible to determine if treatment is needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Oral rinses",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Salt-water gargles are an old stand-by for relief of throat pain. It is not clear if this treatment is effective, but it is unlikely to be harmful. Most recipes suggest",
"       <span class=\"nowrap\">",
"        1/4",
"       </span>",
"       to",
"       <span class=\"nowrap\">",
"        1/2",
"       </span>",
"       teaspoon of salt per cup (8 ounces) of warm water. The water should be gargled and then spit out (not swallowed). Children younger than six to eight years are not able to gargle properly.",
"      </li>",
"      <li>",
"       An oral rinse composed of equal parts of diphenhydramine (Benadryl&reg; liquid) and Maalox&reg; (magnesium hydroxide, aluminum hydroxide, and simethicone) may be helpful for pain caused by a sore mouth or ulcers in the mouth. Children older than six to eight years may swish and spit (not swallow) the mixture.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Sprays",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sprays containing topical anesthetics are available to treat sore throat. However, such sprays are no more effective than sucking on hard candy. In addition, a common anesthetic ingredient, benzocaine, can cause allergic reactions. We do not recommend throat sprays for children.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Lozenges",
"     </span>",
"     &nbsp;&mdash;&nbsp;A variety of medicated throat lozenges are available to relieve dryness or pain. However, it is not clear that lozenges work any better than hard candy. We do not recommend throat lozenges for children, especially children younger than three to four years, who can choke. Sucking on hard candy may provide some relief for children older than three to four years, who are not at risk for choking.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Other interventions",
"     </span>",
"     &nbsp;&mdash;&nbsp;Other interventions include sipping warm beverages (eg, honey or lemon tea, chicken soup), cold beverages, or eating cold or frozen desserts (eg, ice cream, popsicles). These treatments are safe for children. Honey should not be given to children younger than 12 months due to the potential risk of botulism poisoning.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Alternative therapies",
"     </span>",
"     &nbsp;&mdash;&nbsp;Health food stores, vitamin outlets, and Internet Web sites offer alternative treatments for relief of sore throat pain. We do not recommend these treatments due to the risks of contamination with",
"     <span class=\"nowrap\">",
"      pesticides/herbicides,",
"     </span>",
"     inaccurate labeling and dosing information, and a lack of studies showing that these treatments are safe and effective.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      SORE THROAT PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     Hand washing is an essential and highly effective way to prevent the spread of infection. Hands should be wet with water and plain soap, and rubbed together for 15 to 30 seconds. Special attention should be paid to the fingernails, between the fingers, and the wrists. Hands should be rinsed thoroughly, and dried with a single use towel.",
"    </p>",
"    <p>",
"     Alcohol-based hand rubs are a good alternative for disinfecting hands if a sink is not available. Hand rubs should be spread over the entire surface of hands, fingers, and wrists until dry, and may be used several times. These rubs can be used repeatedly without skin irritation or loss of effectiveness. Hand rubs are available as a liquid or wipe in small, portable sizes that are easy to carry in a pocket or handbag. When a sink is available, visibly soiled hands should be washed with soap and water.",
"    </p>",
"    <p>",
"     Hands should be washed after coughing, blowing the nose or sneezing. While it is not always possible to limit contact with a person who is sick, the spread of infection can be prevented if touching of the eyes, nose or mouth are avoided.",
"    </p>",
"    <p>",
"     In addition, tissues should be used to cover the mouth when sneezing or coughing. These used tissues should be disposed of promptly.",
"     <span class=\"nowrap\">",
"      Sneezing/coughing",
"     </span>",
"     into the sleeve of one's clothing (at the inner elbow) is another means of containing sprays of saliva and secretions and has the advantage of not contaminating the hands.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H21\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     Parents of a child with throat pain and one or more of the following should contact their healthcare provider immediately:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Difficulty swallowing or breathing",
"      </li>",
"      <li>",
"       Excessive drooling in an infant or young child",
"      </li>",
"      <li>",
"       Temperature &ge;101&ordm;F or 38.3&ordm;C",
"      </li>",
"      <li>",
"       Swelling of the neck",
"      </li>",
"      <li>",
"       Inability or unwillingness to drink or eat",
"      </li>",
"      <li>",
"       &ldquo;Hot potato&rdquo; or muffled voice",
"      </li>",
"      <li>",
"       Difficulty opening the mouth",
"      </li>",
"      <li>",
"       Stiff neck",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11285141\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11285148\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/26/28066?source=see_link\">",
"      Patient information: Sore throat in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/57/914?source=see_link\">",
"      Patient information: Sore throat in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/34/8738?source=see_link\">",
"      Patient information: Strep throat in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/59/43955?source=see_link\">",
"      Patient information: Swollen neck nodes in children (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/59/40881?source=see_link\">",
"      Patient information: Scarlet fever (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/29/26066?source=see_link\">",
"      Patient information: Laryngitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/1/11282?source=see_link\">",
"      Patient information: Tonsillectomy and adenoidectomy in children (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11285172\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/15/36082?source=see_link\">",
"      Patient information: Sore throat in adults (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11285188\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/38/6758?source=see_link\">",
"      Antibiotic failure in the treatment of streptococcal tonsillopharyngitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/30/27110?source=see_link\">",
"      Complications of streptococcal tonsillopharyngitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39415?source=see_link\">",
"      Evaluation of sore throat in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/11/8377?source=see_link\">",
"      Periodic fever with aphthous stomatitis, pharyngitis and adenitis (PFAPA syndrome)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=see_link\">",
"      Peritonsillar cellulitis and abscess",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/37/27224?source=see_link\">",
"      Symptomatic relief of sore throat in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=see_link\">",
"      Tonsillectomy and adenoidectomy in children",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/38/2666?source=see_link\">",
"      Treatment and prevention of streptococcal tonsillopharyngitis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/sorethroat.html\">",
"      www.nlm.nih.gov/medlineplus/sorethroat.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Nemours Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://kidshealth.org/teen/infections/bacterial_viral/strep_throat.html\">",
"      file://kidshealth.org/teen/infections/bacterial_viral/strep_throat.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?3/22/3427/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?3/22/3427?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3427/abstract/1\">",
"      Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis 2012; 55:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3427/abstract/2\">",
"      Gerber MA. Diagnosis and treatment of pharyngitis in children. Pediatr Clin North Am 2005; 52:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3427/abstract/3\">",
"      Del Mar CB, Glasziou PP, Spinks AB. Antibiotics for sore throat. Cochrane Database Syst Rev 2006; :CD000023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3427/abstract/4\">",
"      King BR. An evidence-based approach to the evaluation and treatment of pharyngitis in children. Pediatric Emerg Med Pract 2007; 4:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3427/abstract/5\">",
"      Martin JM. Pharyngitis and streptococcal throat infections. Pediatr Ann 2010; 39:22.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f3_22_3427=[""].join("\n");
var outline_f3_22_3427=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           SORE THROAT OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           SORE THROAT CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           SORE THROAT DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           SORE THROAT TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           SORE THROAT PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H21\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/28/8641\" title=\"figure 1\">",
"           Strep throat PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f3_22_3428="Aminolevulinic acid: Drug information";
var content_f3_22_3428=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aminolevulinic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/24/29059?source=see_link\">",
"    see \"Aminolevulinic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F133386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levulan&reg; Kerastick&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F133387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Levulan&reg; Kerastick&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F133401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Photosensitizing Agent, Topical;",
"     </li>",
"     <li>",
"      Topical Skin Product",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F133389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Actinic keratoses: Topical: Apply to actinic keratoses (",
"     <b>",
"      not",
"     </b>",
"     perilesional skin) followed 14-18 hours later by blue light illumination. Application/treatment may be repeated at a treatment site (once) after 8 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F133390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F133371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, topical, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levulan&reg; Kerastick&reg;: 20% (6s) [contains ethanol 48% (in diluent); supplied with diluent]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F133357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F133373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dab lesion gently with wet applicator tip (apply enough to uniformly wet lesion without excess running or dripping). Only apply to affected skin. Do not apply to periorbital area, ocular tissue, or mucosal surfaces. Allow to dry, then reapply to same lesion. Apply to either scalp or facial lesions, but not to both simultaneously. Follow application with blue light exposure in 14-18 hours. Do not wash the application area during the time between application and photosensitization; after photosensitization, gently rinse actinic keratosis with water and pat dry. Stinging or burning may occur during blue light treatment. Following blue light treatment, the lesion will temporarily redden, swell and/or scale, which should resolve within 4 weeks after treatment.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F133372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of minimally to moderately thick actinic keratoses (grade 1 or 2) of the face or scalp; to be used in conjunction with blue light illumination",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F8107429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Photodynamic treatment of low-risk superficial basal cell skin cancer and low-risk squamous cell skin cancer",
"     <i>",
"      in situ",
"     </i>",
"     (Bowen&rsquo;s disease)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8107428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aminolevulinic acid may be confused with methyl aminolevulinate",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F133399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Transient stinging, burning, itching, erythema, and edema result from the photosensitizing properties of this agent. Symptoms subside between 1 minute and 24 hours after turning off the blue light illuminator. Severe stinging or burning was reported in at least 50% of patients from at least 1 lesional site during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%: Dermatologic: Stinging or burning (most patients; severe: &ge;50%), erythema (99%), scaling/crusted skin (64% to 71%), hyper-/hypopigmentation (22% to 36%), edematous lesions (35%), itching (14% to 25%), erosion (2% to 14%), skin disorder (5% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dysesthesia (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Vesiculation (4% to 5%), skin ulceration (2% to 4%), pustular drug eruption (&le;4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Bleeding/hemorrhage (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Wheal/flare (2% to 7%), scabbing (&le;2%), tenderness (1% to 2%), edema (&le;1%), excoriation (&le;1%), local pain (&le;1%), oozing (&le;1%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F133376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aminolevulinic acid or any component of the formulation; individuals with cutaneous photosensitivity at wavelengths of 400-450 nm; porphyria; allergy to porphyrins",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F133361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Treatment site will become photosensitive following application. Patients should be instructed to avoid exposure to sunlight, bright indoor lights, or tanning beds during the period prior to blue light treatment. Exposure may result in lesion burning, edema, erythema, and/or stinging. Sunscreen will not protect against visible light; head should be covered with light-opaque material or wide-brimmed hat. If unable to return the next day for blue light treatment, avoid sunlight/bright light exposure to treated lesions for at least 40 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin irritation: Excessive irritation may occur if applied under occlusion.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     &bull; Coagulation defects: Has not been tested in individuals with coagulation defects (acquired or inherited).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitizing agents: Concomitant use of other known photosensitizing agents may increase the degree of photosensitivity reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For external use only. Do not apply to eyes or mucous membranes. Application should involve either scalp or face lesions, although not simultaneously. Should be applied by a qualified health professional to avoid application to perilesional skin.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F133366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F133368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F133378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted, and there are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F133392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Levulan Kerastick External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20% (1): $214.24",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F133379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      ALA (CL);",
"     </li>",
"     <li>",
"      Hexvix (AT, GR);",
"     </li>",
"     <li>",
"      Levulan Kerastick (TH);",
"     </li>",
"     <li>",
"      Metvix (AR, AU, BE, BR, CH, CN, CZ, DE, DK, FI, GB, IE, IT, NL, NO, NZ, PT, SE, SG, ZA);",
"     </li>",
"     <li>",
"      Metvixia (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F133360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aminolevulinic acid is a metabolic precursor of the photosensitizer protoporphyrin IX (PpIX). Photosensitization following local application of aminolevulinic acid occurs through the metabolic conversion to PpIX. When exposed to light of appropriate wavelength and energy, accumulated PpIX produces a photodynamic reaction resulting in local cytotoxicity. Precancerous and cancerous cells exhibit a higher rate of porphyrin induction compared to normal cells.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F133375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peak fluorescence intensity of protoporphyrin IX (PpIX): Actinic keratosis: 11 hours &plusmn; 1 hour; Perilesional skin: 12 hours &plusmn; 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Mean fluorescence clearance half-life of PpIX for lesions: 30 &plusmn; 10 hours",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Braathen LR, Szeimies RM, Basset-Seguin N, et al, &ldquo;Guidelines on the Use of Photodynamic Therapy for Nonmelanoma Skin Cancer: An International Consensus. International Society for Photodynamic Therapy in Dermatology, 2005,&rdquo;",
"      <i>",
"       J Am Acad Dermatol",
"      </i>",
"      , 2007, 56(1):125-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/22/3428/abstract-text/17190630/pubmed\" id=\"17190630\" target=\"_blank\">",
"        17190630",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moloney FJ and Collins P, et al, &ldquo;Randomized, Double-Blind, Prospective Study to Compare Topical 5-Aminolaevulinic Acid Methylester With Topical 5-Aminolaevulinic Acid Photodynamic Therapy for Extensive Scalp Actinic Keratosis,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      , 2007, 157(1):87-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/22/3428/abstract-text/17501954/pubmed\" id=\"17501954\" target=\"_blank\">",
"        17501954",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Basal Cell and Squamous Cell Skin Cancers,&rdquo; Version 1.2009. Available at  file://www.nccn.org/professionals/physician_gls/PDF/nmsc.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tierney E, Barker A, Ahdout J, et al, &ldquo;Photodynamic Therapy for the Treatment of Cutaneous Neoplasia, Inflammatory Disorders, and Photoaging,&rdquo;",
"      <i>",
"       Dermatol Surg",
"      </i>",
"      , 2009, 35(5):725-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/22/3428/abstract-text/19309338/pubmed\" id=\"19309338\" target=\"_blank\">",
"        19309338",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9199 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-200.167.4.114-B6D75EF485-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_22_3428=[""].join("\n");
var outline_f3_22_3428=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133386\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133387\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133401\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133389\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133390\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133371\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133357\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133373\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133372\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107429\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107428\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133399\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133376\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133361\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298736\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133366\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133368\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133378\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133392\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322982\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133379\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133360\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F133375\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9199\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9199|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/24/29059?source=related_link\">",
"      Aminolevulinic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_22_3429="Natalizumab for treatment of Crohn's disease in adults";
var content_f3_22_3429=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Natalizumab for treatment of Crohn's disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/22/3429/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3429/contributors\">",
"     Joshua R Korzenik, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/22/3429/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3429/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/22/3429/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3429/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/22/3429/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    (Tysabri&reg;) is a humanized monoclonal antibody to alpha-4 integrin that was initially approved for treatment of multiple sclerosis and more recently for Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3429/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is generally reserved for patients with moderate to severe Crohn&rsquo;s disease that is refractory to other forms of medical therapy.",
"   </p>",
"   <p>",
"    This topic will review the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    in the treatment of Crohn&rsquo;s disease. Other approaches to the medical management of Crohn&rsquo;s disease are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29559?source=see_link\">",
"     \"Adalimumab for treatment of Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33829?source=see_link\">",
"     \"Certolizumab pegol for treatment of Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/40/10886?source=see_link\">",
"     \"Budesonide in the treatment of Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=see_link\">",
"     \"Antibiotics for treatment of inflammatory bowel diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    blocks leukocyte migration from the blood vessels to sites of inflammation by inhibiting the action of cell adhesion molecules. Cell adhesion molecules represent a heterogeneous group of transmembrane molecules expressed on numerous cell types, including endothelial cells and leukocytes. Cell adhesion molecules promote the transmigration of leukocytes across the endothelial cell. The particular molecule targeted by natalizumab is alpha-4 integrin, which is expressed on all circulating leukocytes except neutrophils.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5930522\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    is indicated for inducing and maintaining clinical response and remission in adult patients with Crohn&rsquo;s disease. Patients being considered for natalizumab must have:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Moderately to severely active Crohn's disease",
"     </li>",
"     <li>",
"      Evidence of inflammation",
"     </li>",
"     <li>",
"      Failed alternative forms of therapy, including an inadequate response to, or an inability to tolerate, conventional Crohn's disease therapies and inhibitors of TNF-alpha",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    is intended for use as monotherapy. It should not be used in patients who may have impaired immunity, are taking immunosuppressants, or are taking TNF inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3429/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. We suggest stopping glucocorticoids within a few months of initiation of natalizumab. A two-month washout is reasonable for",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"      azathioprine",
"     </a>",
"     /6",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , anti-TNF agents, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3429/abstract/3\">",
"     3",
"    </a>",
"    ]. Leukocyte and neutrophil counts should be within or close to the normal range prior to starting therapy.",
"   </p>",
"   <p>",
"    Due to serious adverse events, the drug is available only through a prescribing program (CD-TOUCH&trade; Prescribing Program, Biogen Idec, Weston, MA). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Adverse events'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Information on the CD-TOUCH&trade; Prescribing Program can be obtained from Biogen Idec",
"    <span class=\"nowrap\">",
"     (https://medinfo.biogenidec.com/medinfo",
"    </span>",
"    or 1-800-456-2255).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5930745\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    is given as an intravenous infusion and must be administered at an infusion center that is registered with the TOUCH&reg; Prescribing Program. Typically, 300 mg are given at weeks 0, 4, and 8, and then given every four weeks for maintenance. If a patient has had no response by week 12, the drug is discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    was shown to be superior to placebo in a meta-analysis that included five trials [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3429/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients treated with natalizumab were less likely to fail to achieve remission than patients treated with placebo (RR 0.88).",
"   </p>",
"   <p>",
"    Two of the trials included in the meta-analysis showed the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest trial, Efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       Natalizumab",
"      </a>",
"      as Active Crohn&rsquo;s Therapy (ENACT-1) trial, included a total of 905 patients with active Crohn's disease who were randomly assigned to natalizumab (300 mg) or placebo at weeks 0, 4, and 8 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3429/abstract/2\">",
"       2",
"      </a>",
"      ]. Response, defined by a decrease in the Crohn's Disease Activity Index (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?5/61/6098?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) of at least 70 points at week 10, was similar to placebo (56 versus 49 percent). A post-hoc analysis of the results in patients with elevated CRP at baseline showed efficacy for natalizumab compared with placebo.",
"      <br/>",
"      <br/>",
"      The 339 responders to natalizumab were enrolled in a follow-up trial (ENACT-2) in which they were randomly reassigned to receive 300 mg of natalizumab or placebo every four weeks through week 56 [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3429/abstract/2\">",
"       2",
"      </a>",
"      ]. Patients receiving natalizumab had significantly higher rates of sustained response (61 versus 28 percent) and remission (44 versus 26 percent) through week 36, as well as higher discontinuation rates of glucocorticoids.",
"     </li>",
"     <li>",
"      A second trial, Efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       Natalizumab",
"      </a>",
"      in Crohn&rsquo;s Disease Response and Remission (ENCORE) trial, included 509 patients with moderately to severely active Crohn's disease and active inflammation (CRP &gt;2.87",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3429/abstract/6\">",
"       6",
"      </a>",
"      ]. The patients were randomly assigned to natalizumab (300 mg) or placebo at weeks 0, 4, and 8. The primary end point was induction of a response, defined as a &ge;70 point reduction in the CDAI at week eight and sustained through week 12. A response was observed significantly more often in patients assigned to natalizumab (48 versus 32 percent). In addition, sustained remission (CDAI &lt;150) was observed significantly more often with natalizumab (26 versus 16 percent). The frequency and types of adverse events were similar between treatment groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ADVERSE EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious adverse events occurred at a similar rate to the placebo arm in two controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3429/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. However, in an open-label extension, one patient with Crohn&rsquo;s disease on monotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    died from JC virus-associated progressive multifocal leukoencephalopathy (PML). Two other case reports described an association between natalizumab and PML in patients with multiple sclerosis treated with natalizumab and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/10/8358?source=see_link\">",
"     interferon beta-1a",
"    </a>",
"    (Avonex&reg;) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3429/abstract/7\">",
"     7",
"    </a>",
"    ]. Latent JC virus infection and viral shedding are common in immunosuppressed patients with Crohn's disease, but risk factors of JC-related disease are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3429/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, marketing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    was suspended in February 2005 but was subsequently resumed for multiple sclerosis. At least 270 additional cases of PML have occurred in patients with multiple sclerosis since the drug was reintroduced, with a 20 percent mortality rate and a high degree of disability among survivors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3429/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23032?source=see_link&amp;anchor=H4#H4\">",
"     \"Natalizumab for relapsing-remitting multiple sclerosis in adults\", section on 'Risk of progressive multifocal leukoencephalopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of PML is associated with duration of treatment, with no increased risk observed in the initial year of therapy. Prior immune suppressant medication use appears to increase the risk as well [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3429/abstract/9\">",
"     9",
"    </a>",
"    ]. Because of the risk of PML,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    is available for the treatment of Crohn's disease only through a special restricted distribution program called the CD-TOUCH&trade; Prescribing Program. Natalizumab is not approved for use in Crohn's disease in Europe. (See",
"    <a class=\"local\" href=\"#H5930522\">",
"     'Indications and contraindications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A test for JC virus antibody is commercially available and may be a reliable marker for those at higher risk of developing PML. Use of the JC virus antibody assay has been advocated to stratify the risk of PML. For those who are JC virus antibody negative, the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    is likely associated with minimal risk of developing PML. As the rate of acquisition of JC virus may be as much as 1 percent annually, the frequency of JC virus antibody testing is uncertain but at least once a year would be advisable for those being administered natalizumab.",
"   </p>",
"   <p>",
"    Severe cholestatic liver injury has also been reported, prompting the manufacturer to issue a warning in February 2008. Affected patients developed marked elevation in serum aminotransferases and bilirubin as soon as six days after the first dose. Thus, liver biochemical tests should be monitored and the drug discontinued in patients with evidence of liver injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=see_link\">",
"       \"Patient information: Crohn's disease in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"       \"Patient information: Crohn's disease (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?5/20/5443?source=see_link\">",
"       \"Patient information: Inflammatory bowel disease and pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       Natalizumab",
"      </a>",
"      is a humanized monoclonal antibody to alpha-4 integrin approved as a second-line agent for patients with moderate to severe Crohn's disease who have not responded to other therapies. It is available only through a restricted prescribing program because of the risk of JC virus-associated progressive multifocal leukoencephalopathy. (See",
"      <a class=\"local\" href=\"#H5930522\">",
"       'Indications and contraindications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Adverse events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       Natalizumab",
"      </a>",
"      should not be used in patients who may have impaired immunity, are taking immunosuppressants, or are taking TNF inhibitors. Leukocyte and neutrophil counts should be within or close to the normal range prior to starting therapy. Natalizumab is contraindicated in patients who have hematologic or rheumatologic conditions associated with compromised cell-mediated immunity. (See",
"      <a class=\"local\" href=\"#H5930522\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In two pivotal clinical trials, the drug was approximately 10 to 15 percent more effective than placebo in achieving a clinical response and 10 to 30 percent more effective in maintaining a response. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      be reserved for patients with Crohn's disease with the indications described above, provided that the risks have been explained to the patient (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5930522\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who do not have antibodies to the JC virus likely have a minimal risk of developing PML and the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"       natalizumab",
"      </a>",
"      might be considered. Those who are antibody positive have an increased risk, particularly after a year of use, and the use of natalizumab should limited.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3429/abstract/1\">",
"      Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3429/abstract/2\">",
"      Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3429/abstract/3\">",
"      Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007; 6:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3429/abstract/4\">",
"      Ransohoff RM. Natalizumab for multiple sclerosis. N Engl J Med 2007; 356:2622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3429/abstract/5\">",
"      Ford AC, Sandborn WJ, Khan KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3429/abstract/6\">",
"      Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007; 132:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3429/abstract/7\">",
"      Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3429/abstract/8\">",
"      Verbeeck J, Van Assche G, Ryding J, et al. JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy? Gut 2008; 57:1393.",
"     </a>",
"    </li>",
"    <li>",
"     Biogen Idec Medical Information Web Site. https://medinfo.biogenidec.com/medinfo/registration/reguser.do (Accessed on January 19, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4050 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-447D2A5374-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_22_3429=[""].join("\n");
var outline_f3_22_3429=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5930522\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5930745\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ADVERSE EVENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?5/61/6098?source=related_link\" title=\"calculator 1\">",
"      Calculator: Crohn's disease activity index (CDAI)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29559?source=related_link\">",
"      Adalimumab for treatment of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=related_link\">",
"      Antibiotics for treatment of inflammatory bowel diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/40/10886?source=related_link\">",
"      Budesonide in the treatment of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/2/33829?source=related_link\">",
"      Certolizumab pegol for treatment of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23032?source=related_link\">",
"      Natalizumab for relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=related_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/20/5443?source=related_link\">",
"      Patient information: Inflammatory bowel disease and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_22_3430="Tetanus toxoid (adsorbed): Drug information";
var content_f3_22_3430=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tetanus toxoid (adsorbed): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/5/12371?source=see_link\">",
"    see \"Tetanus toxoid (adsorbed): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/52/24389?source=see_link\">",
"    see \"Tetanus toxoid (adsorbed): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F226116\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Bacterial)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F226109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In most patients, Td is the recommended product for primary immunization, booster doses, and tetanus immunization in wound management (refer to Diphtheria and Tetanus Toxoid monograph).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Primary immunization:",
"     </b>",
"     I.M.: 0.5 mL; repeat 0.5 mL at 4-8 weeks after first dose and at 6-12 months after second dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Routine booster dose:",
"     </b>",
"     Recommended every 10 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Tetanus prophylaxis in wound management:",
"     </b>",
"     Tetanus prophylaxis in patients with wounds should consider if the wound is clean or contaminated, the immunization status of the patient, proper use of tetanus toxoid and/or tetanus immune globulin (TIG), wound cleaning, and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until &gt;10 years after the most recent dose even if they have a wound that is neither clean nor minor. See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption style=\"text-align:center;\">",
"      Tetanus Prophylaxis in Wound Management",
"     </caption>",
"     <col align=\"center\" width=\"145\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <col align=\"center\" width=\"85\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\" rowspan=\"2\" valign=\"middle\">",
"        <p style=\"text-indent:0em;\">",
"         History of Tetanus Immunization Doses",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Clean, Minor Wounds",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         All Other Wounds",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Tetanus Toxoid",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         TIG",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Tetanus Toxoid",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         TIG",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"middle\">",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; wounds from crushing, tears, burns, and frostbite.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Tetanus toxoid in this chart refers to a tetanus toxoid-containing vaccine. For children &lt;7 years of age, DTaP (DT, if pertussis vaccine contraindicated) is preferred to tetanus toxoid alone. For children &ge;7 years and Adults, Td preferred to tetanus toxoid alone; Tdap may be preferred if the patient has not previously been vaccinated with Tdap.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          3",
"         </sup>",
"         Yes, if &ge;10 years since last dose.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          4",
"         </sup>",
"         Yes, if &ge;5 years since last dose.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         Adapted from CDC \"Yellow Book\" (",
"         <i>",
"          Health Information for International Travel 2010",
"         </i>",
"         ), \"Routine Vaccine-Preventable Diseases, Tetanus\" (available at",
"         <a href=\"file://www.cdc.gov/yellowbook\" target=\"_blank\">",
"          file://www.cdc.gov/yellowbook",
"         </a>",
"         ) and",
"         <i>",
"          MMWR",
"         </i>",
"         2006, 55(RR-17).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\" valign=\"top\">",
"        <p style=\"text-indent:0em;\">",
"         Abbreviations:",
"         <b>",
"          DT",
"         </b>",
"         = Diphtheria and Tetanus Toxoids (formulation for age &le;6 years);",
"         <b>",
"          DTaP",
"         </b>",
"         = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (formulation for age &le;6 years; Daptacel&reg;, Infanrix&reg;);",
"         <b>",
"          Td",
"         </b>",
"         = Diphtheria and Tetanus Toxoids (formulation for age &ge;7 years; Decavac&reg;,Tenivac&trade;);",
"         <b>",
"          TT",
"         </b>",
"         = Tetanus toxoid (adsorbed [formulation for age &ge;7 years]);",
"         <b>",
"          Tdap",
"         </b>",
"         = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (Adacel&reg; or Boostrix&reg; [formulations for age &ge;7 years]);",
"         <b>",
"          TIG",
"         </b>",
"         = Tetanus Immune Globulin",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"middle\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          Uncertain or &lt;3 doses",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Yes",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Yes",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Yes",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         <b>",
"          3 or more doses",
"         </b>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"         <sup>",
"          4",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F226112\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/52/24389?source=see_link\">",
"      see \"Tetanus toxoid (adsorbed): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;7 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F226110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F226097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension: 5 Lf units/0.5 mL (0.5 mL) [contains aluminum and thimerosal (may have trace amounts]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F226084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F226100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inject intramuscularly in the area of the vastus lateralis (midthigh laterally) or deltoid. Do not inject into gluteal area. Shake well prior to withdrawing dose; do not use if product does not form a suspension.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     For patients at risk of hemorrhage following intramuscular injection, the ACIP recommends &ldquo;it should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection.&rdquo; Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. The use of licensed combination vaccines is generally preferred over separate injections of the equivalent components. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F226098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Active immunization against tetanus when combination antigen preparations are not indicated; tetanus prophylaxis in wound management.",
"     <b>",
"      Note:",
"     </b>",
"     Tetanus and diphtheria toxoids for adult use (Td) is the preferred immunizing agent for most adults and for children after their seventh birthday. Young children should receive trivalent DTaP (diphtheria/tetanus/acellular pertussis) as part of their childhood immunization program, unless pertussis is contraindicated, then DT is warranted.",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F226122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tetanus toxoid products may be confused with influenza virus vaccine and tuberculin products. Medication errors have occurred when tetanus toxoid products have been inadvertently administered instead of tuberculin skin tests (PPD) and influenza virus vaccine. These products are refrigerated and often stored in close proximity to each other.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F226114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Brachial neuritis, fever, malaise, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Edema, induration (with or without tenderness), rash, redness, urticaria, warmth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular: Arthralgia, Guillain-Barr&eacute; syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reaction, Arthus-type hypersensitivity reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F226103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to tetanus toxoid or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F226088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arthus-type hypersensitivity: Tetanus containing vaccines and emergency doses of tetanus vaccine should not be given more frequently than every 10 years in patients who have experienced a serious Arthus-type hypersensitivity reaction following a prior use of tetanus toxoid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute febrile illness.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Guillain-Barr&eacute; syndrome: Use with caution if Guillain-Barr&eacute; syndrome occurred within 6 weeks of prior tetanus toxoid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines:  In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual component.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunocompromised patients: Patients who are immunocompromised may have reduced response; may be used in patients with HIV infection. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;7 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thimerosal: Product may contain thimerosal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Avoid injection into a blood vessel.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F226092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F226094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F744551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Animal studies have not been conducted. Inactivated bacterial vaccines have not been shown to cause increased risks to the fetus (CDC, 2011). The ACIP recommends vaccination in previously unvaccinated women or in women with an incomplete vaccination series, whose child may be born in unhygienic conditions. Tetanus immune globulin and a tetanus toxoid-containing vaccine are recommended by the ACIP as part of the standard wound management to prevent tetanus in pregnant women. Vaccination using Td is preferred.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6742574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F11864695\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inactivated vaccines do not affect the safety of breast-feeding for the mother or the infant. Breast-feeding infants should be vaccinated according to the recommended schedules (CDC, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Tetanus Toxoid Adsorbed Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 lfu (0.5 mL): $46.01",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13908785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F226087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tetanus toxoid preparations contain the toxin produced by virulent tetanus bacilli (detoxified growth products of",
"     <i>",
"      Clostridium tetani",
"     </i>",
"     ). The toxin has been modified by treatment with formaldehyde so that it has lost toxicity but still retains ability to act as antigen and produce active immunity; the aluminum salt, a mineral adjuvant, delays the rate of absorption and prolongs and enhances its properties; duration ~10 years.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F226102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Duration: Primary immunization: ~10 years",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bentley DW, &ldquo;Vaccinations,&rdquo;",
"      <i>",
"       Clin Geriatr Med",
"      </i>",
"      , 1992, 8(4):745-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/22/3430/abstract-text/1423132/pubmed\" id=\"1423132\" target=\"_blank\">",
"        1423132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Prevention of Pertussis, Tetanus, and Diphtheria Among Pregnant and Postpartum Women and Their Infants. Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2008, 57(RR-4):1-51; published erratum appears in",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(26):723.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/22/3430/abstract-text/18509304/pubmed\" id=\"18509304\" target=\"_blank\">",
"        18509304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/22/3430/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gardner P and Schaffner W, &ldquo;Immunization of Adults,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 328(17):1252-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/22/3430/abstract-text/8464436/pubmed\" id=\"8464436\" target=\"_blank\">",
"        8464436",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/22/3430/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?3/22/3430/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9984 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-89768E4622-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_22_3430=[""].join("\n");
var outline_f3_22_3430=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226116\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226109\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226112\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226110\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226097\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226084\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226100\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226098\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226122\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226114\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226103\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226088\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300120\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226092\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226094\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F744551\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6742574\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11864695\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323953\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13908785\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226087\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226102\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9984\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9984|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/5/12371?source=related_link\">",
"      Tetanus toxoid (adsorbed): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/52/24389?source=related_link\">",
"      Tetanus toxoid (adsorbed): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_22_3431="Anatomy and clinical significance of pancreas divisum";
var content_f3_22_3431=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anatomy and clinical significance of pancreas divisum",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/22/3431/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3431/contributors\">",
"     Evan Fogel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3431/contributors\">",
"     Stuart Sherman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/22/3431/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3431/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/22/3431/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3431/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/22/3431/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital anomalies and variants of the pancreas are seen in approximately 10 percent of the general population and are therefore not uncommon at endoscopic retrograde cholangiopancreatography (ERCP) (",
"    <a class=\"graphic graphic_table graphicRef52761 \" href=\"UTD.htm?16/24/16779\">",
"     table 1",
"    </a>",
"    ). While many are found coincidentally at endoscopy, surgery, or autopsy, a portion of these anomalies and variants are clinically significant and cause symptoms in childhood or adulthood.",
"   </p>",
"   <p>",
"    Pancreas divisum is the most common congenital pancreatic anomaly, occurring in approximately 7 percent of subjects in autopsy series (range 1 to 14 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The frequency with which pancreas divisum is seen at ERCP depends upon the number of patients with pancreatitis in the study population and the completeness of pancreatography.",
"   </p>",
"   <p>",
"    In one retrospective series of 1825 successful consecutive ERCPs, pancreas divisum was found in 7.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/3\">",
"     3",
"    </a>",
"    ]. It was significantly more common in patients presenting with idiopathic pancreatitis (up to 50 percent) than in controls or in the general population. In another, large retrospective study from India, pancreas divisum was more frequent in patients with pancreatitis than in those with biliary diseases or obscure abdominal pain (9 versus 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic review will discuss the anatomy and controversies surrounding the clinical significance of pancreas divisum and the endoscopic retrograde cholangiopancreatographic techniques used to establish the diagnosis. Issues related to the surgical or endoscopic correction of the minor papilla narrowing associated with pancreas divisum in symptomatic patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15271?source=see_link\">",
"     \"Treatment of pancreas divisum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PANCREATIC DUCT DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pancreas is formed from fusion of the dorsal and ventral anlage which develop from the embryologic foregut (",
"    <a class=\"graphic graphic_figure graphicRef78995 \" href=\"UTD.htm?18/24/18822\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/5\">",
"     5",
"    </a>",
"    ]. The ventral system also gives rise to the hepatobiliary system. At approximately the eighth intrauterine week of life, the ventral pancreas rotates posterior to the duodenum and comes to rest posterior and inferior to the head portion of the dorsal pancreas.",
"   </p>",
"   <p>",
"    Parenchymal fusion nearly always occurs, although a tissue plane may be evident histologically, surgically, ultrasonographically, or radiographically between the dorsal and the ventral pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Pancreatic parenchymal textural or contour differences may be evident between the dorsal and ventral pancreas in up to 75 percent of normal individuals when observed via endoscopic ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/6\">",
"     6",
"    </a>",
"    ]. The ventral pancreas also can be differentiated from the dorsal pancreas by its relatively high pancreatic polypeptide content on immunohistochemistry [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The ventral pancreas represents 2 to 20 percent of the pancreatic parenchymal mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pancreas divisum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fusion of the ductal system occurs in just over 90 percent of individuals, although variations in patency of the accessory duct (of Santorini) occur. Failure of fusion of the ventral and dorsal duct system results in pancreas divisum. Several different types can occur:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classic pancreas divisum anatomy consists of a small ventral duct which drains through the larger major papilla and the larger dorsal duct which drains through the smaller minor papilla (",
"      <a class=\"graphic graphic_figure graphicRef78995 \" href=\"UTD.htm?18/24/18822\">",
"       figure 1",
"      </a>",
"      ). In some cases, the entire pancreatic ductal system drains through the minor papilla via the dorsal duct.",
"     </li>",
"     <li>",
"      In incomplete pancreas divisum, a small branch of the ventral duct communicates with the dorsal duct.",
"      <br/>",
"      <br/>",
"      Approximately 15 percent of cases of pancreas divisum are of the incomplete type [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/10-12\">",
"       10-12",
"      </a>",
"      ]. However, the clinical implications of incomplete pancreas divisum are the same as for classic (or complete) pancreas divisum, except that modest to full visualization of the dorsal duct may occur with vigorous major papillary contrast injection.",
"     </li>",
"     <li>",
"      A \"reverse\" divisum also can occur in which there is an isolated small segment of dorsal pancreas. This occurs when the accessory duct of Santorini does not connect with the genu of the main pancreatic duct. This anomaly has physiologic significance in that the overflow valve to the main ductal system is absent. Thus, a gallstone that is impacted at the major papilla will likely cause more severe pancreatitis. In addition, non-filling of the duct of Santorini can mimic malignant obstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pancreas divisum can be associated with other pancreatobiliary abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately one-third of patients with annular pancreas also have pancreas divisum, a setting in which rotational and fusional abnormalities coexist [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18293?source=see_link\">",
"       \"Annular pancreas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Up to one-half of patients with pancreas divisum have elevated sphincter of Oddi basal pressures [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/15-17\">",
"       15-17",
"      </a>",
"      ]. The frequency of pain relief from major papilla sphincterotomy alone in such cases is uncertain.",
"     </li>",
"     <li>",
"      Pancreas divisum also may be associated with partial agenesis of the dorsal pancreas [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. While initial data suggested that there may be an increased risk of cholangiocarcinoma in patients with pancreas divisum [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/20\">",
"       20",
"      </a>",
"      ], more recent data suggest that this is not the case [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Numerous case reports have associated pancreas divisum with other conditions such as pancreatic cancer, panniculitis, intestinal malrotation, choledochal cysts, hereditary pancreatitis, and hepatic hamartoma. Since pancreas divisum occurs in at least 5 percent of the general population, these case reports may represent only chance associations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is estimated that fewer than 5 percent of patients with pancreas divisum develop pancreatic symptoms. The low frequency of symptoms has created a controversy as to whether pancreas divisum and its associated small minor papilla orifice are ever a cause of obstructive pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/22-27\">",
"     22-27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=see_link&amp;anchor=H17#H17\">",
"     \"Etiology of acute pancreatitis\", section on 'Pancreas divisum'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The arguments against an association are based upon two major observations. First, some studies have found that the incidence of pancreas divisum is the same in patients with and without pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/26\">",
"     26",
"    </a>",
"    ]. Second, symptoms occur infrequently in patients with this anomaly. Nevertheless, we believe that there is a group of patients with pancreas divisum who are subject to recurrent bouts of seemingly idiopathic pancreatitis. In these patients, the minor papilla orifice is so small that excessively high intrapancreatic dorsal ductal pressure occurs during active secretion, which may result in inadequate drainage, ductal distension, pain, and, in some cases, pancreatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/3,28-31\">",
"     3,28-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one review, for example, 60 percent of patients with pancreas divisum and otherwise unexplained abdominal pain had relief of the pain after surgical sphincteroplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/28\">",
"     28",
"    </a>",
"    ]. In addition, among 119 patients with this congenital anomaly who had recurrent acute pancreatitis, treatment by either surgical or endoscopic papillotomy of the minor papilla resulted in relief from further attacks of acute pancreatitis in 80 percent.",
"   </p>",
"   <p>",
"    Acute pancreatitis associated with pancreas divisum tends to be mild but pseudocysts, calculi, and other more severe complications are occasionally seen [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/32-37\">",
"     32-37",
"    </a>",
"    ]. It has also been suggested that even low-grade intraductal hypertension makes the pancreas more prone to injury from alcohol, trauma, and drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/38\">",
"     38",
"    </a>",
"    ]. Since the causative lesion is relative stenosis of the minor papilla rather than pancreas divisum per se, some authorities prefer to call this condition the dominant dorsal duct syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/15,39\">",
"     15,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical settings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pancreas divisum is made in one of three clinical settings: as a coincident finding; in patients with minimal symptoms; and in patients with moderate to severe pain or pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Coincidental finding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreas divisum ductal anatomy is clearly coincidental and can be ignored when this anomaly is detected in the setting of common duct stones, sclerosing cholangitis, or other liver parenchymal conditions, and the patient has no CT scan abnormality of the pancreas or a clinical history of pancreatitis. Furthermore, pancreas divisum is probably an asset in the setting of a common duct stone; serious gallstone pancreatitis is probably not possible, since gallstone obstruction at the major papilla will only block the small ventral duct. In addition, major papilla sphincterotomy may be performed more aggressively because only a small portion of the pancreas may be disturbed. In rare cases, the minor papilla is on the cephalad rim of the longitudinal fold to the major papilla [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/40\">",
"     40",
"    </a>",
"    ]. This must be recognized to avoid injury during standard biliary sphincterotomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Minimal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pancreas divisum and mild or infrequent bouts of pain or pancreatitis can generally be managed conservatively with a low-fat diet, analgesics, anticholinergics, and, if necessary, pancreatic enzyme supplements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of chronic pancreatitis\", section on 'Pancreatic enzyme supplements'",
"    </a>",
"    .) It is controversial whether persons with mild symptoms should have aggressive therapy in hopes of preventing progression to more advanced disease. We currently favor a conservative approach, although the correct degree of aggressiveness is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Moderate to severe pain or pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pancreas divisum and recurrent pancreatobiliary-type pain or pancreatitis associated with clinically significant disability warrant thorough evaluation of the dorsal pancreas and minor papilla. We generally evaluate the dorsal pancreas and perform minor papilla therapy in patients having two or more bouts of pancreatitis or one bout of severe pancreatitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15271?source=see_link\">",
"     \"Treatment of pancreas divisum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pancreas divisum is usually made by endoscopic retrograde cholangiopancreatography (ERCP) in patients presenting with pancreatobiliary symptoms. Magnetic resonance cholangiopancreatography (MRCP) has also been used successfully [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/41\">",
"     41",
"    </a>",
"    ]. Stimulation of pancreatic flow with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    can improve ductal visualization during MRCP. (See",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     \"Secretin: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pancreas divisum is associated with two potential problems at ERCP. First, only the ventral pancreas portion of the pancreas can be viewed by standard major papilla cannulation. The dorsal pancreas is not evaluated unless minor papilla cannulation and dorsal ductography is also performed. Second, the small ventral duct must be differentiated from various forms of main pancreatic duct cutoff, such as pancreatic cancer or a benign stricture; this distinction can be difficult if the pancreatogram is incomplete.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Visualization of the dorsal duct",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minor papilla cannulation is essential for full evaluation of the dorsal system (dorsal ductography) in patients with pancreas divisum. General indications for minor papilla cannulation include cases in which a ventral duct is seen by major papilla injection or pancreatography cannot be attained via the major papilla. In experienced hands, minor papilla cannulation can be achieved in approximately 90 to 95 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/10,26\">",
"     10,26",
"    </a>",
"    ]. Failures are usually associated with minor papilla distortion from inflammation (eg, pancreatitis or peptic ulcer disease), diverticula, or tumor.",
"   </p>",
"   <p>",
"    The minor papilla is nearly always located in the right upper quadrant of the visual field when facing the major papilla. It may be as close as 10 mm to or, more often, as far as 2 to 3 cm (cephalad and anterior) from the major papilla.",
"   </p>",
"   <p>",
"    Cannulation is generally best achieved with the endoscope pushed into the long position along the greater curve of the stomach. The highly tapered 5 Fr catheter with a 23- or 25-gauge blunt needle tip protruding 1 to 2 mm beyond the catheter tip is the most helpful in achieving cannulation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The remainder of the procedure, including contrast media and fluoroscopic techniques, are similar to conventional ERCP.",
"   </p>",
"   <p>",
"    The minor papilla orifice is not evident initially in approximately one-third of cases. In such patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    (16 mcg) can be given intravenously; the ensuing substantial increase in pancreatic exocrine juice flow leads to visibly evident orifice dilation. In a controlled trial involving 29 patients in whom cannulation was initially unsuccessful, the administration of synthetic porcine secretin (ChiRhoClin, Inc, Silver Spring, MD) permitted cannulation in 90 percent of patients compared to 6 percent who received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    is not without risk during pancreatography. Although there were no adverse events in the above report, in the presence of vigorous juice flow, it may be difficult to force contrast media retrograde into the pancreatic tail, possibly predisposing to pancreatitis. As a result, the administration of secretin should be limited to difficult cases and pancreatic tail visualization should be limited unless there is a strong clinical indication.",
"   </p>",
"   <p>",
"    In some patients,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    stimulation does not produce a visible increase in pancreatic juice flow. In this setting, the orifice may become apparent after spraying a dilute (1:10)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    solution over the face of the minor papilla; clear juice will wash away the background blue dye at the orifice [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3431/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In approximately 2 percent of patients, dorsal ductography shows an isolated small ductal system (isolated dorsal segment) which can simulate a typical ventral pancreas. Once detected, the major papilla must be cannulated to view the main pancreatic duct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pancreas divisum is the most common congenital pancreatic anomaly, occurring in approximately 7 percent of subjects in autopsy series (range 1 to 14 percent). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of pancreas divisum is usually made by endoscopic retrograde cholangiopancreatography (ERCP) in patients presenting with pancreatobiliary symptoms. Magnetic resonance cholangiopancreatography (MRCP) has also been used successfully. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is estimated that fewer than 5 percent of patients with pancreas divisum develop pancreatic symptoms. The low frequency of symptoms has created a controversy as to whether pancreas divisum and its associated small minor papilla orifice are ever a cause of obstructive pancreatitis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We believe that there is a group of patients with pancreas divisum who are subject to recurrent bouts of seemingly idiopathic pancreatitis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.) An approach to recognizing such patients is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15271?source=see_link\">",
"       \"Treatment of pancreas divisum\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We generally evaluate the dorsal pancreas and perform minor papilla therapy in patients having two or more bouts of pancreatitis or one bout of severe pancreatitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15271?source=see_link\">",
"       \"Treatment of pancreas divisum\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/1\">",
"      Smanio T. Proposed nomenclature and classification of the human pancreatic ducts and duodenal papillae. Study based on 200 post mortems. Int Surg 1969; 52:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/2\">",
"      Stimec B, Bulaji M, Korneti V, et al. Ductal morphometry of ventral pancreas in pancreas divisum. Comparison between clinical and anatomical results. Ital J Gastroenterol 1996; 28:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/3\">",
"      Bernard JP, Sahel J, Giovannini M, Sarles H. Pancreas divisum is a probable cause of acute pancreatitis: a report of 137 cases. Pancreas 1990; 5:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/4\">",
"      Dhar A, Goenka MK, Kochhar R, et al. Pancrease divisum: five years' experience in a teaching hospital. Indian J Gastroenterol 1996; 15:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/5\">",
"      Kozu T, Suda K, Toki F. Pancreatic development and anatomical variation. Gastrointest Endosc Clin N Am 1995; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/6\">",
"      Savides TJ, Gress FG, Zaidi SA, et al. Detection of embryologic ventral pancreatic parenchyma with endoscopic ultrasound. Gastrointest Endosc 1996; 43:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/7\">",
"      Zeman RK, McVay LV, Silverman PM, et al. Pancreas divisum: thin-section CT. Radiology 1988; 169:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/8\">",
"      Dowsett JF, Rode J, Russell RC. Annular pancreas: a clinical, endoscopic, and immunohistochemical study. Gut 1989; 30:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/9\">",
"      Sessa F, Fiocca R, Tenti P, et al. Pancreatic polypeptide rich tissue in the annular pancreas. A distinctive feature of ventral primordium derivatives. Virchows Arch A Pathol Anat Histopathol 1983; 399:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/10\">",
"      Benage D, McHenry R, Hawes RH, et al. Minor papilla cannulation and dorsal ductography in pancreas divisum. Gastrointest Endosc 1990; 36:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/11\">",
"      Moreira VF, Mero&ntilde;o E, Ledo L, et al. Incomplete pancreas divisum. Gastrointest Endosc 1991; 37:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/12\">",
"      Ng JW, Wong MK, Huang J, Chan YT. Incomplete pancreas divisum associated with abnormal junction of pancreaticobiliary duct system. Gastrointest Endosc 1992; 38:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/13\">",
"      Lehman GA, O'Connor KW. Coexistence of annular pancreas and pancreas divisum--ERCP diagnosis. Gastrointest Endosc 1985; 31:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/14\">",
"      England RE, Newcomer MK, Leung JW, Cotton PB. Case report: annular pancreas divisum--a report of two cases and review of the literature. Br J Radiol 1995; 68:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/15\">",
"      Madura JA. Pancreas divisum: stenosis of the dorsally dominant pancreatic duct. A surgically correctable lesion. Am J Surg 1986; 151:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/16\">",
"      Madura JA, Fiore AC, O'Connor KW, et al. Pancreas divisum. Detection and management. Am Surg 1985; 51:353.",
"     </a>",
"    </li>",
"    <li>",
"     Gregg JA. Function and dysfunction of the sphincter of Oddi. In: ERCP: Diagnostic and Therapeutic Applications, Jacobson IM (Ed), Elsevier Science, New York 1989. p.139.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/18\">",
"      Lehman GA, Kopecky KK, Rogge JD. Partial pancreatic agenesis combined with pancreas divisum and duodenum reflexum. Gastrointest Endosc 1987; 33:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/19\">",
"      Wildling R, Schnedl WJ, Reisinger EC, et al. Agenesis of the dorsal pancreas in a woman with diabetes mellitus and in both of her sons. Gastroenterology 1993; 104:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/20\">",
"      Nugent C, Ruffolo T, Hawes R, et al. Is pancreas divisum associated with biliary tract carcinoma? Gastrointest Endosc 1993; 39:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/21\">",
"      Fatima H, Malcolm M, Sherman S, et al. Pancreas divisum: a retrospective review to evaluate the risk of biliary tract neoplasms. Pract Gastroenterol 2007; 31:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/22\">",
"      Burtin P, Person B, Charneau J, Boyer J. Pancreas divisum and pancreatitis: a coincidental association? Endoscopy 1991; 23:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/23\">",
"      Carr-Locke DL. Pancreas divisum: the controversy goes on? Endoscopy 1991; 23:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/24\">",
"      Cotton PB. Pancreas divisum--curiosity or culprit? Gastroenterology 1985; 89:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/25\">",
"      Delhaye M, Cremer M. Clinical significance of pancreas divisum. Acta Gastroenterol Belg 1992; 55:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/26\">",
"      Delhaye M, Engelholm L, Cremer M. Pancreas divisum: congenital anatomic variant or anomaly? Contribution of endoscopic retrograde dorsal pancreatography. Gastroenterology 1985; 89:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/27\">",
"      Fogel EL, Toth TG, Lehman GA, et al. Does endoscopic therapy favorably affect the outcome of patients who have recurrent acute pancreatitis and pancreas divisum? Pancreas 2007; 34:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/28\">",
"      Lehman GA, Sherman S. Pancreas divisum. Diagnosis, clinical significance, and management alternatives. Gastrointest Endosc Clin N Am 1995; 5:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/29\">",
"      Cotton PB. Congenital anomaly of pancreas divisum as cause of obstructive pain and pancreatitis. Gut 1980; 21:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/30\">",
"      Gregg JA. Pancreas divisum: its association with pancreatitis. Am J Surg 1977; 134:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/31\">",
"      Krueger KJ, Wootton FT 3rd, Cunningham JT, Hoffman BJ. Unexpected anomalies of the common bile and pancreatic ducts. Am J Gastroenterol 1992; 87:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/32\">",
"      Foley TR, McGarrity TJ. Transient changes of dorsal pancreatic duct in acute pancreatitis associated with pancreas divisum. Dig Dis Sci 1990; 35:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/33\">",
"      Browder W, Gravois E, Vega P, Ertan A. Obstructing pseudocyst of the duct of Santorini in pancreas divisum. Am J Gastroenterol 1987; 82:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/34\">",
"      Cobb BW, Meyer KK, Cotton PB. Recurrent pseudocysts and pancreatitis after trauma: a complication of pancreas divisum. Surgery 1985; 97:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/35\">",
"      Robert JY, Bretagne JF, Raoul JL, et al. Recurrent cholangitis caused by the migration of pancreatic calculi associated with pancreas divisum. Gastrointest Endosc 1993; 39:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/36\">",
"      Simmons TC, Henderson DR, Gletten F. Pancreatic abscess associated with pancreas divisum. J Natl Med Assoc 1988; 80:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/37\">",
"      V&aacute;zquez-Iglesias JL, Durana JA, Ya&ntilde;ez J, et al. Santorinirrhage: hemosuccus pancreaticus in pancreas divisum. Am J Gastroenterol 1988; 83:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/38\">",
"      Lowes JR, Rode J, Lees WR, et al. Obstructive pancreatitis: unusual causes of chronic pancreatitis. Br J Surg 1988; 75:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/39\">",
"      Warshaw AL, Simeone JF, Schapiro RH, Flavin-Warshaw B. Evaluation and treatment of the dominant dorsal duct syndrome (pancreas divisum redefined). Am J Surg 1990; 159:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/40\">",
"      Venu RP, Deutsch SF, Laurent L, et al. Absent minor papilla and an unusual drainage system in a patient with pancreas divisum. Gastrointest Endosc 1995; 42:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/41\">",
"      Bret PM, Reinhold C, Taourel P, et al. Pancreas divisum: evaluation with MR cholangiopancreatography. Radiology 1996; 199:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/42\">",
"      McCarthy J, Fumo D, Geenen JE. Pancreas divisum: a new method for cannulating the accessory papilla. Gastrointest Endosc 1987; 33:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/43\">",
"      O'Connor KW, Lehman GA. An improved technique for accessory papilla cannulation in pancreas divisum. Gastrointest Endosc 1985; 31:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/44\">",
"      Devereaux BM, Fein S, Purich E, et al. A new synthetic porcine secretin for facilitation of cannulation of the dorsal pancreatic duct at ERCP in patients with pancreas divisum: a multicenter, randomized, double-blind comparative study. Gastrointest Endosc 2003; 57:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3431/abstract/45\">",
"      Park SH, de Bellis M, McHenry L, et al. Use of methylene blue to identify the minor papilla or its orifice in patients with pancreas divisum. Gastrointest Endosc 2003; 57:358.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5653 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_22_3431=[""].join("\n");
var outline_f3_22_3431=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PANCREATIC DUCT DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pancreas divisum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical settings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Coincidental finding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Minimal symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Moderate to severe pain or pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Visualization of the dorsal duct",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/5653\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5653|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/24/18822\" title=\"figure 1\">",
"      Anatomy embryology pancreas div",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/5653|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/24/16779\" title=\"table 1\">",
"      Congenital pancreatic anomalies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/55/18293?source=related_link\">",
"      Annular pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14297?source=related_link\">",
"      Etiology of acute pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/49/28435?source=related_link\">",
"      Secretin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31369?source=related_link\">",
"      Treatment of chronic pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15271?source=related_link\">",
"      Treatment of pancreas divisum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_22_3432="Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)";
var content_f3_22_3432=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/22/3432/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3432/contributors\">",
"     Terry F Davies, MD, FRCP, FACE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/22/3432/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3432/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/22/3432/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3432/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/22/3432/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eye disease often associated with Graves' thyroid disease is referred to as Graves' ophthalmopathy. However, it is primarily a disease of the orbit and has also been called Graves' orbitopathy. This topic review will provide an overview of the pathogenesis and clinical features of Graves' ophthalmopathy, which is an autoimmune disease of the retroorbital tissues. Treatment of this disorder is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35239?source=see_link\">",
"     \"Treatment of Graves' orbitopathy (ophthalmopathy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of Graves' ophthalmopathy is becoming more clearly understood. The volume of both the extraocular muscles and retroorbital connective and adipose tissue is increased, due to inflammation and the accumulation of hydrophilic glycosaminoglycans (GAG), principally hyaluronic acid, in these tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. GAG secretion by fibroblasts is increased by activated T-cell cytokines such as tumor necrosis factor (TNF) alpha and interferon gamma, implying that T-cell activation is an important part of this immunopathology. The accumulation of GAG causes a change in osmotic pressure, which in turn leads to a fluid accumulation and an increase in pressure within the orbit. These changes displace the eyeball forward and can also interfere with the function of the extraocular muscles and the venous drainage of the orbits.",
"   </p>",
"   <p>",
"    On histologic examination, the extraocular muscles are swollen, and some muscle fibers show loss of striation, fragmentation, and infiltration with lymphocytes, most of which are T lymphocytes (",
"    <a class=\"graphic graphic_picture graphicRef59356 \" href=\"UTD.htm?29/13/29911\">",
"     picture 1",
"    </a>",
"    ). The following observations suggest that these T cells may play a central role in the development of ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In vitro studies of retroorbital tissue from patients with Graves' ophthalmopathy have shown that the infiltrating T cells are activated by retroorbital tissue fractions.",
"     </li>",
"     <li>",
"      Retroorbital fibroblasts secrete GAG in response to cytokines such as interferon gamma and TNF alpha secreted by helper (CD4+) T cells of the Th1 type.",
"     </li>",
"     <li>",
"      Some of the muscle cells and fibroblasts express HLA class II antigens, as seen on thyroid cells in patients with autoimmune thyroid disease, which suggests they can present antigen to T cells and resident dendritic cells, thereby serving to perpetuate if not initiate the pathological process [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/3-5\">",
"       3-5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      T cells isolated from retroorbital tissue (similar to those isolated from thyroid tissue) have limited V-region genotypes [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/6,7\">",
"       6,7",
"      </a>",
"      ] and the same genotypes have been seen in the thyroid and retroorbital tissues.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Autoantibodies to various components of retroorbital tissues, particularly components of extraocular muscle cells, have been detected in the serum of patients with Graves' ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. However, these are secondary markers of the inflammatory process and not unique to Graves' disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antigen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial activation of T cells in Graves' ophthalmopathy is now thought to be initiated by thyrotropin (TSH) receptor antigen. Mechanistic observations, plus the fact that Graves' hyperthyroidism and Graves' ophthalmopathy often occur concomitantly, have led to the suggestion that activation of the immune system must be secondary to an antigen shared by both tissues. The presence of TSH receptor mRNA and protein in orbital fibroblasts and adipocytes has provoked speculation that this receptor may be the antigen involved in the pathogenesis of ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/1,7,12-14\">",
"     1,7,12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not only can TSH receptor mRNA and protein be detected in orbital fibroblasts and adipocytes but pre-adipocytes from patients with Graves' ophthalmopathy may also express more TSH receptor mRNA and produce more cyclic AMP in response to TSH than do similar cells from normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/15\">",
"     15",
"    </a>",
"    ]. These cells are thought to be derived from a subset of fibroblasts and differentiate ultimately into adipocytes.",
"   </p>",
"   <p>",
"    Although evidence for extra-thyroidal TSH receptor expression is widespread [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/16\">",
"     16",
"    </a>",
"    ], the evidence that TSHR expression is greater in the retroorbital tissues of Graves' patients when compared to that found elsewhere is compelling. In fact, only small amounts of TSH receptor protein are found in orbital fibroblasts from normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/17,18\">",
"     17,18",
"    </a>",
"    ] and it disappears when the fibroblasts are cultured in vitro for prolonged periods [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Hence, in addition to TSHR antigen directly activating specific T cells, these observations suggest that TSHR expression in vivo is dependent upon an external stimulus from the local inflammatory cells or even external to the eye, such as from TSH receptor antibodies.",
"   </p>",
"   <p>",
"    The role of TSH receptor antibodies in the pathogenesis of Graves' hyperthyroidism is no longer in doubt. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=see_link\">",
"     \"Pathogenesis of Graves' disease\"",
"    </a>",
"    .) The observation of a correlation between the severity of ophthalmopathy and serum TSH receptor antibody concentrations is also compatible with the hypothesis that these antibodies, and not just T cells, may play an important role in the eye disease by activating fibroblast and adipocyte TSH receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/7\">",
"     7",
"    </a>",
"    ]. Low levels of TSHR stimulation have a positive effect on TSHR mRNA and expression [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other autoantigens may be involved in the pathogenesis of ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/22\">",
"     22",
"    </a>",
"    ] but they are most likely to be secondary in importance. As an example, it has also been suggested that antibodies to the ubiquitous IGF-1 receptor may accentuate the action of TSHR antibodies in patients with Graves' disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/23\">",
"     23",
"    </a>",
"    ]. As another example, thyroglobulin (of thyroid origin) has been identified in extracts of orbital tissue from three patients with Graves' ophthalmopathy but not in two patients without thyroid or eye disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors may increase the risk of ophthalmopathy in patients with Graves' disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence for a genetic component to the pathogenesis of Graves' hyperthyroidism applies equally to the ophthalmopathy. A family history of Graves' disease or Hashimoto's disease, the presence of other autoimmune diseases in the patients and their relatives, and a high percentage of concordance in identical twins, depending on their age, all point toward a major genetic component in these disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/25\">",
"     25",
"    </a>",
"    ]. There is, however, no confirmed, reproducible evidence of a distinct genetic risk for eye disease, despite publications to the contrary. While families have been described with a number of individuals affected with ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/26\">",
"     26",
"    </a>",
"    ], in practice it is unusual to obtain such a history [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Certain HLA haplotypes have been associated with the presence of eye disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/27\">",
"     27",
"    </a>",
"    ], but this has not been a common observation and appears more likely to be the same as for all patients with Graves'.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graves' ophthalmopathy, like hyperthyroidism, is more common in women than men. However, men who have ophthalmopathy are more likely to have an increase in severity during follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/28\">",
"     28",
"    </a>",
"    ]. The explanation for this may be that men often have more severe Graves' disease for unclear reasons.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cigarette smoking is a confirmed risk factor for Graves' ophthalmopathy. As an example, in a large study from the Netherlands, the odds ratio for ophthalmopathy was 7.7 in smokers compared with nonsmokers. Furthermore, among patients with ophthalmopathy, smokers were more likely to have more severe disease than nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Smoking is associated with an increase in the connective tissue volume of the orbit, but not the extraocular muscle volumes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/30\">",
"     30",
"    </a>",
"    ]. How this might occur is not known, but direct toxic effects of smoke on the inflamed eyes are likely and immunologic changes have been described in smokers that could affect the autoimmune process [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, in vitro data suggest that cigarette smoke stimulates glycosaminoglycan production and adipogenesis in a dose-dependent manner [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Type of treatment for Graves' disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of treatment given for Graves' thyroid disease may be a risk factor for ophthalmopathy. In particular, radioiodine therapy may be more likely to lead to the development or worsening of ophthalmopathy than antithyroid drug therapy or subtotal thyroidectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35239?source=see_link\">",
"     \"Treatment of Graves' orbitopathy (ophthalmopathy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thyrotropin receptor autoantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;High titers of thyrotropin receptor autoantibodies have long been known to correlate with the most severe cases of Graves' disease (the Graves' Triad of thyroid, eye, and skin involvement). As the measurement of these antibodies has become more precise (measured as TSH competing antibodies), it appears that even in patients with milder disease, there is an independent correlation between these autoantibodies and the prevalence and course of ophthalmopathy during presentation and follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other possible risk factors for Graves' ophthalmopathy include advancing age (&gt;60 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/28\">",
"     28",
"    </a>",
"    ] and stress [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/11,25\">",
"     11,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 20 to 25 percent of patients with Graves' hyperthyroidism have clinically obvious Graves' ophthalmopathy, not just the eye signs of thyroid hormone excess (lid retraction and stare), at the time of diagnosis of the hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/2\">",
"     2",
"    </a>",
"    ]. However, many more patients with Graves' hyperthyroidism have evidence of ophthalmopathy, primarily enlargement of retroocular muscles, on ultrasonography, computed tomography (CT), or magnetic resonance (MR) imaging of the orbits [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. In a study of MR imaging in 17 patients with no clinical findings of ophthalmopathy, 12 had extraocular muscle enlargement, which was bilateral in eight [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The estimated incidence of Graves' ophthalmopathy in the general population is 16 women and three men per 100,000 population per year [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similarly, most patients with ophthalmopathy have evidence of thyroid disease, but in approximately 10 percent of patients it is absent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/1,37\">",
"     1,37",
"    </a>",
"    ]. Such patients are labeled as having \"euthyroid\" Graves' disease, but they may still have high serum antithyroid autoantibody concentrations or circulating thyroid-specific T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/38\">",
"     38",
"    </a>",
"    ]. Sometimes ophthalmopathy occurs in patients with classical chronic autoimmune thyroiditis (Hashimoto's disease), and these patients may have TSHR receptor antibodies of the blocking variety.",
"   </p>",
"   <p>",
"    There is usually a temporal relationship between the ophthalmopathy and the onset of hyperthyroidism. The ophthalmopathy appears before the onset of hyperthyroidism in approximately 20 percent of patients, concurrently in about 40 percent, and in the six months after diagnosis in about 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/39\">",
"     39",
"    </a>",
"    ]. In the remainder, the eye disease first becomes apparent after treatment of the hyperthyroidism, more often in patients treated with radioiodine [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35239?source=see_link&amp;anchor=H3#H3\">",
"     \"Treatment of Graves' orbitopathy (ophthalmopathy)\", section on 'Antithyroid treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic signs of Graves' ophthalmopathy are proptosis and periorbital edema (",
"    <a class=\"graphic graphic_figure graphicRef72169 \" href=\"UTD.htm?42/43/43699\">",
"     figure 1",
"    </a>",
"    ). The patient may have no ocular symptoms, may be distressed by the appearance of his or her eyes, or may be symptomatic. The major symptoms include one or more of the following: a sense of irritation in the eyes; excessive tearing that is often made worse by exposure to cold air, wind, or bright lights; eye or retroorbital discomfort or pain; blurring of vision; diplopia; and occasionally loss of vision.",
"   </p>",
"   <p>",
"    The degree of proptosis (exophthalmos) is dependent on the depth of the orbit and the degree of enlargement of the retroocular muscles and retroorbital fibrous and fatty tissue. The proptosis may be usually symmetric, but is often asymmetric, and may be accompanied by a sensation of pressure behind the eyeballs. The proptosis may be masked by periorbital edema, which is a common accompaniment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with hyperthyroidism have lid retraction secondary to thyroid hormone excess, leading to stare and lid lag (due to contraction of the levator palpebrae muscles of the eyelids). The stare may give the appearance of proptosis, when none in fact exists (\"apparent proptosis\"). These signs alone do not indicate the presence of ophthalmopathy, and subside when the hyperthyroidism is treated.",
"   </p>",
"   <p>",
"    Physical examination of the eyes of a patient with Graves' ophthalmopathy should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inspection of the conjunctivae and periorbital tissue, looking for conjunctival injection and edema (chemosis) and periorbital edema.",
"     </li>",
"     <li>",
"      Determination of the extent to which the upper and lower lids can be closed, because failure of apposition promotes drying and ulceration of the cornea.",
"     </li>",
"     <li>",
"      Assessment of the range of motion of the eyes. Impairment of extraocular muscle function is often evident by an inability to achieve or maintain convergence. Limitation of upward gaze may be present, leading to a characteristic head-back position in order to see ahead. Muscle dysfunction also leads to double vision, initially on extremes of gaze, and eventually in almost all directions, necessitating use of appropriate lenses or an eye patch.",
"     </li>",
"     <li>",
"      Objective measurements of the degree of proptosis, using an exophthalmometer. These instruments permit measurement of the distance between the lateral angle of the bony orbit and an imaginary line tangent to the most anterior part of the cornea. The upper limit of normal is 20 mm in whites and 22 mm in blacks. The values may be as high as 30 mm in patients with severe proptosis.",
"     </li>",
"     <li>",
"      Visual acuity and color vision should be assessed by simple reading tests and color charts, and visual fields should be evaluated by confrontation. If any evidence of impairment is obtained, the patient should be evaluated by an ophthalmologist.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rare patients have extreme forms of ophthalmopathy, which can threaten vision. The forms include subluxation of the globe due to severe proptosis, ulceration or infection of the cornea secondary to an inability to close the lids, and optic neuropathy caused by compression of the optic nerve at the apex of the orbit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6906?source=see_link&amp;anchor=H24#H24\">",
"     \"Congenital anomalies and acquired abnormalities of the optic nerve\", section on 'Compression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The correlation between the symptoms and signs of ophthalmopathy is often poor. While attention to the physical findings is important in considering prognosis and therapy, it is equally important to listen to what the patient says about his or her symptoms and changes in the symptoms. As an example, a clinician may be tempted to intervene in some way because the patient has rather marked proptosis, even though there are no severe symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Assessment of severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of examination described above provides the basis for the routine evaluation of most patients. However, for improved objectivity, a classification of the eye changes of Graves' disease developed by the American Thyroid Association has become widely used [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/35\">",
"     35",
"    </a>",
"    ]. The first letters of each category constitute the mnemonic NO SPECS &mdash; NO connotes absence or mild degree of involvement; SPECS the more serious degrees of involvement.",
"   </p>",
"   <p>",
"    The severity therefore ranges from 0 to VI.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Class 0 &mdash;",
"      <strong>",
"       N",
"      </strong>",
"      o symptoms or signs",
"     </li>",
"     <li>",
"      Class I &mdash;",
"      <strong>",
"       O",
"      </strong>",
"      nly signs, no symptoms (eg, lid retraction, stare, lid lag)",
"     </li>",
"     <li>",
"      Class II &mdash;",
"      <strong>",
"       S",
"      </strong>",
"      oft tissue involvement",
"     </li>",
"     <li>",
"      Class III &mdash;",
"      <strong>",
"       P",
"      </strong>",
"      roptosis",
"     </li>",
"     <li>",
"      Class IV &mdash;",
"      <strong>",
"       E",
"      </strong>",
"      xtraocular muscle involvement",
"     </li>",
"     <li>",
"      Class V &mdash;",
"      <strong>",
"       C",
"      </strong>",
"      orneal involvement",
"     </li>",
"     <li>",
"      Class VI &mdash;",
"      <strong>",
"       S",
"      </strong>",
"      ight loss (optic nerve involvement)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, NO SPECS is not always satisfactory for prospective objective assessment of orbital changes [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/41\">",
"     41",
"    </a>",
"    ], and determining an overall activity score is sometimes more helpful. This is done by assigning one point for the presence of each of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Spontaneous retrobulbar pain",
"     </li>",
"     <li>",
"      Pain on eye movement",
"     </li>",
"     <li>",
"      Eyelid erythema",
"     </li>",
"     <li>",
"      Conjunctival injection",
"     </li>",
"     <li>",
"      Chemosis",
"     </li>",
"     <li>",
"      Swelling of the caruncle",
"     </li>",
"     <li>",
"      Eyelid edema",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A photographic atlas of eye findings has also been developed, which may be helpful for ophthalmologic assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some reports suggest that urinary glycosaminoglycan concentrations and somatostatin-receptor imaging with 111-indium-labeled pentetreotide correlate well with the clinical activity of Graves' ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/43-46\">",
"     43-46",
"    </a>",
"    ]. The uptake of this radionuclide has also been suggested to have value in predicting responsiveness to anti-inflammatory therapy in patients with ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/44-46\">",
"     44-46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of Graves' ophthalmopathy in most patients is obvious, because of the combination of the characteristic ocular abnormalities described above and hyperthyroidism. It is, however, important to differentiate the eye signs of Graves' ophthalmopathy from the eye signs of thyroid hormone excess (stare and lid lag), which can also occur in other forms of hyperthyroidism such as toxic multinodular goiter. Bilateral eye signs simulating Graves' ophthalmopathy can also be present in patients with severe obesity, Cushing's syndrome, orbital myositis, histiocytosis, myasthenia gravis, and very rarely with orbital tumors or as a manifestation of statin-induced extraocular muscle myopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=see_link\">",
"     \"Ocular myasthenia gravis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link&amp;anchor=H4#H4\">",
"     \"Statin myopathy\", section on 'Myalgias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unilateral Graves' ophthalmopathy may be considerably more difficult to diagnose in the absence of thyroid dysfunction, and must be differentiated from space-occupying lesions of the orbit.",
"   </p>",
"   <p>",
"    When necessary, the diagnosis can be confirmed by ultrasonography, CT or MRI of the orbits, which show swelling of the extraocular muscles and increased retroorbital fat in virtually all patients with Graves' ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/34,47\">",
"     34,47",
"    </a>",
"    ]. We prefer CT because of the extensive normative data available on intraorbital volumes, the better bone visualization, and the lower cost compared with MRI (",
"    <a class=\"graphic graphic_table graphicRef59823 \" href=\"UTD.htm?20/30/20971\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/47\">",
"     47",
"    </a>",
"    ]. It is important not to inject iodinated contrast material in patients with Graves' disease especially if radioiodine therapy is contemplated.",
"   </p>",
"   <p>",
"    In patients in whom the diagnosis is not in doubt, the only testing that is necessary is measurement of serum TSH, free thyroxine, and TSHR antibodies. Measurements of serum TSH receptor antibodies can be helpful in confirming an obvious diagnosis, but also in assessing the severity of the condition and monitoring the patient's response to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3432/abstract/33,48\">",
"     33,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"       \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graves' ophthalmopathy, an autoimmune disease of the retroorbital tissues, occurs in 20 to 25 percent of patients with Graves' disease (more commonly in women than men). Important features include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The volume of both the extraocular muscles and retroorbital connective and adipose tissue is increased, due to inflammation and the accumulation of hydrophilic glycosaminoglycans (GAG), principally hyaluronic acid, in these tissues. GAG secretion by fibroblasts is increased by activated T-cell cytokines. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial activation of T cells in Graves' ophthalmopathy is thought to be initiated by thyrotropin (TSH) receptor antigen. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antigen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      TSH receptor antibodies, and not just T cells, may play an important role in the eye disease by activating fibroblast and adipocyte TSH receptors. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antigen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for the development of Graves' ophthalmopathy include genetics, female sex, smoking, and possibly radioiodine therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ophthalmopathy appears before the onset of hyperthyroidism in approximately 20 percent of patients, concurrently in about 40 percent, in the six months after diagnosis in about 20 percent, and after treatment for Graves' hyperthyroidism in the remainder (most commonly after radioiodine therapy). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severity of disease can be assessed using the NO SPECS classification or with an overall activity score. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of Graves' ophthalmopathy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35239?source=see_link\">",
"     \"Treatment of Graves' orbitopathy (ophthalmopathy)\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/1\">",
"      Bahn RS. Graves' ophthalmopathy. N Engl J Med 2010; 362:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/2\">",
"      Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and management. Endocr Rev 1993; 14:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/3\">",
"      Weetman AP, Cohen S, Gatter KC, et al. Immunohistochemical analysis of the retrobulbar tissues in Graves' ophthalmopathy. Clin Exp Immunol 1989; 75:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/4\">",
"      Wall JR, Salvi M, Bernard NF, et al. Thyroid-associated ophthalmopathy--a model for the association of organ-specific autoimmune disorders. Immunol Today 1991; 12:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/5\">",
"      Grubeck-Loebenstein B, Trieb K, Sztankay A, et al. Retrobulbar T cells from patients with Graves' ophthalmopathy are CD8+ and specifically recognize autologous fibroblasts. J Clin Invest 1994; 93:2738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/6\">",
"      Heufelder AE, Herterich S, Ernst G, et al. Analysis of retroorbital T cell antigen receptor variable region gene usage in patients with Graves' ophthalmopathy. Eur J Endocrinol 1995; 132:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/7\">",
"      Davies TF. The thyrotropin receptors spread themselves around. J Clin Endocrinol Metab 1994; 79:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/8\">",
"      Kodama K, Sikorska H, Bandy-Dafoe P, et al. Demonstration of a circulating autoantibody against a soluble eye-muscle antigen in Graves' ophthalmopathy. Lancet 1982; 2:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/9\">",
"      Bahn RS, Gorman CA, Johnson CM, Smith TJ. Presence of antibodies in the sera of patients with Graves' disease recognizing a 23 kilodalton fibroblast protein. J Clin Endocrinol Metab 1989; 69:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/10\">",
"      Ross PV, Koenig RJ, Arscott P, et al. Tissue specificity and serologic reactivity of an autoantigen associated with autoimmune thyroid disease. J Clin Endocrinol Metab 1993; 77:433.",
"     </a>",
"    </li>",
"    <li>",
"     Kendler DL, Davies TF. Immunological mechanisms in Graves' disease. In: Molecular Pathology of Autoimmunity, Bona C, Siminovitch K, Theofilopoulos AN, Zanetti M (Eds), Harwood Academic, New York 1993. p.511.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/12\">",
"      Stadlmayr W, Spitzweg C, Bichlmair AM, Heufelder AE. TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathy and pretibial myxedema. Thyroid 1997; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/13\">",
"      Villanueva R, Inzerillo AM, Tomer Y, et al. Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid 2000; 10:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/14\">",
"      Spitzweg C, Joba W, Hunt N, Heufelder AE. Analysis of human thyrotropin receptor gene expression and immunoreactivity in human orbital tissue. Eur J Endocrinol 1997; 136:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/15\">",
"      Valyasevi RW, Erickson DZ, Harteneck DA, et al. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J Clin Endocrinol Metab 1999; 84:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/16\">",
"      Davies T, Marians R, Latif R. The TSH receptor reveals itself. J Clin Invest 2002; 110:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/17\">",
"      Bahn RS, Dutton CM, Joba W, Heufelder AE. Thyrotropin receptor expression in cultured Graves' orbital preadipocyte fibroblasts is stimulated by thyrotropin. Thyroid 1998; 8:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/18\">",
"      Bahn RS. Understanding the immunology of Graves' ophthalmopathy. Is it an autoimmune disease? Endocrinol Metab Clin North Am 2000; 29:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/19\">",
"      Bahn RS, Dutton CM, Natt N, et al. Thyrotropin receptor expression in Graves' orbital adipose/connective tissues: potential autoantigen in Graves' ophthalmopathy. J Clin Endocrinol Metab 1998; 83:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/20\">",
"      Bell A, Gagnon A, Grunder L, et al. Functional TSH receptor in human abdominal preadipocytes and orbital fibroblasts. Am J Physiol Cell Physiol 2000; 279:C335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/21\">",
"      Huber GK, Weinstein SP, Graves PN, Davies TF. The positive regulation of human thyrotropin (TSH) receptor messenger ribonucleic acid by recombinant human TSH is at the intranuclear level. Endocrinology 1992; 130:2858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/22\">",
"      McGregor AM. Has the target autoantigen for Graves' ophthalmopathy been found? Lancet 1998; 352:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/23\">",
"      Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol 2008; 181:4397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/24\">",
"      Marin&ograve; M, Lisi S, Pinchera A, et al. Identification of thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy. Thyroid 2001; 11:177.",
"     </a>",
"    </li>",
"    <li>",
"     Davies TF. Graves' disease: Pathogenesis. In: Werner &amp; Ingbar's The Thyroid, 8th, Braverman LE, Utiger RD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2000. p.518.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/26\">",
"      Morrison, H. The familial incidence of exophthalmic goiter. N Engl J Med 1928; 199:85-86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/27\">",
"      Frecker M, Stenszky V, Balazs C, et al. Genetic factors in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1986; 25:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/28\">",
"      Perros P, Crombie AL, Matthews JN, Kendall-Taylor P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin Endocrinol (Oxf) 1993; 38:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/29\">",
"      Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA 1993; 269:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/30\">",
"      Szucs-Farkas Z, Toth J, Kollar J, et al. Volume changes in intra- and extraorbital compartments in patients with Graves' ophthalmopathy: effect of smoking. Thyroid 2005; 15:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/31\">",
"      Costabel U, Bross KJ, Reuter C, et al. Alterations in immunoregulatory T-cell subsets in cigarette smokers. A phenotypic analysis of bronchoalveolar and blood lymphocytes. Chest 1986; 90:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/32\">",
"      Cawood TJ, Moriarty P, O'Farrelly C, O'Shea D. Smoking and thyroid-associated ophthalmopathy: A novel explanation of the biological link. J Clin Endocrinol Metab 2007; 92:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/33\">",
"      Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006; 91:3464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/34\">",
"      Werner SC, Coleman DJ, Franzen LA. Ultrasonographic evidence of a consistent orbital involvement in Graves's disease. N Engl J Med 1974; 290:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/35\">",
"      Villadolid MC, Yokoyama N, Izumi M, et al. Untreated Graves' disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance. J Clin Endocrinol Metab 1995; 80:2830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/36\">",
"      Bartley GB, Fatourechi V, Kadrmas EF, et al. The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota. Am J Ophthalmol 1995; 120:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/37\">",
"      WERNER SC. Euthyroid patients with early eye signs of Graves' disease; their responses to L-triiodothyronine and thyrotropin. Am J Med 1955; 18:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/38\">",
"      Salvi M, Zhang ZG, Haegert D, et al. Patients with endocrine ophthalmopathy not associated with overt thyroid disease have multiple thyroid immunological abnormalities. J Clin Endocrinol Metab 1990; 70:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/39\">",
"      Bartley GB, Fatourechi V, Kadrmas EF, et al. Chronology of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996; 121:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/40\">",
"      Tallstedt L, Lundell G, T&oslash;rring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992; 326:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/41\">",
"      Wartofsky, L. Classification of eye changes of Graves' disease. Thyroid 1992; 3:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/42\">",
"      Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin Endocrinol (Oxf) 2001; 55:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/43\">",
"      Martins JR, Furlanetto RP, Oliveira LM, et al. Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2004; 60:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/44\">",
"      Gerding MN, van der Zant FM, van Royen EA, et al. Octreotide-scintigraphy is a disease-activity parameter in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1999; 50:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/45\">",
"      Moncayo R, Baldissera I, Decristoforo C, et al. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog 111In-octreotide. Thyroid 1997; 7:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/46\">",
"      Ujhelyi B, Erdei A, Galuska L, et al. Retrobulbar 99mTc-diethylenetriamine-pentaacetic-acid uptake may predict the effectiveness of immunosuppressive therapy in Graves' ophthalmopathy. Thyroid 2009; 19:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/47\">",
"      Forbes G, Gorman CA, Brennan MD, et al. Ophthalmopathy of Graves' disease: computerized volume measurements of the orbital fat and muscle. AJNR Am J Neuroradiol 1986; 7:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3432/abstract/48\">",
"      Davies TF, Roti E, Braverman LE, DeGroot LJ. Thyroid controversy--stimulating antibodies. J Clin Endocrinol Metab 1998; 83:3777.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7825 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-1591A33FAF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_22_3432=[""].join("\n");
var outline_f3_22_3432=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Smoking",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Type of treatment for Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thyrotropin receptor autoantibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Assessment of severity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7825\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7825|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/43/43699\" title=\"figure 1\">",
"      Graves retroorbital fat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7825|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/13/29911\" title=\"picture 1\">",
"      Graves eye infiltrate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7825|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/30/20971\" title=\"table 1\">",
"      Orbital muscle and fat CT",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6906?source=related_link\">",
"      Congenital anomalies and acquired abnormalities of the optic nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/53/7001?source=related_link\">",
"      Ocular myasthenia gravis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/30/40425?source=related_link\">",
"      Pathogenesis of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=related_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35239?source=related_link\">",
"      Treatment of Graves' orbitopathy (ophthalmopathy)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_22_3433="Repair of episiotomy and perineal lacerations associated with childbirth";
var content_f3_22_3433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Repair of episiotomy and perineal lacerations associated with childbirth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/22/3433/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3433/contributors\">",
"     Marc R Toglia, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/22/3433/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3433/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/22/3433/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3433/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/22/3433/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;After vaginal delivery, the vagina, perineum, and anorectum are examined to identify and repair significant injuries. In particular, occult injury to the anal sphincter complex occurs frequently at the time of an otherwise uncomplicated delivery and, if neglected, can contribute to anal and fecal incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/1\">",
"     1",
"    </a>",
"    ]. Even when recognized and repaired, persistent sphincter dysfunction is considered to be the most common cause of postpartum anal incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation and repair of episiotomy incisions and perineal lacerations associated with childbirth will be reviewed here. Evaluation and management of vaginal lacerations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44071?source=see_link&amp;anchor=H15#H15\">",
"     \"Evaluation and management of lower genital tract trauma in women\", section on 'Vagina'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscles of the female pelvic floor and perineum are shown in the following figures (",
"    <a class=\"graphic graphic_figure graphicRef62230 \" href=\"UTD.htm?31/63/32756\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef74060 \" href=\"UTD.htm?28/57/29588\">",
"     figure 2",
"    </a>",
"    ). The anorectal sphincter complex is comprised of two structures with different, but overlapping, roles for maintaining continence (",
"    <a class=\"graphic graphic_figure graphicRef62539 \" href=\"UTD.htm?14/30/14819\">",
"     figure 3",
"    </a>",
"    ). The external anal sphincter (EAS) is a thick, circular, predominantly striated muscle that surrounds the anal orifice, and is responsible for continence of solid and liquid stool, as well as flatus, both at rest and at times of rectal distension. The internal anal sphincter (IAS) lies between the external sphincter and the anal canal and represents a thin condensation of the longitudinal smooth muscle fibers of the colon submucosa (",
"    <a class=\"graphic graphic_figure graphicRef62539 \" href=\"UTD.htm?14/30/14819\">",
"     figure 3",
"    </a>",
"    ). The IAS extends more than a centimeter above the cephalad margin of the external sphincter [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/4\">",
"     4",
"    </a>",
"    ]. It is entirely under involuntary control and contributes to maintaining anal continence at rest [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/4\">",
"     4",
"    </a>",
"    ]. The puborectalis portion of the levator ani complex also plays an important role in continence of solid stool. An intact pudendal nerve appears to be important, as well.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1999, Sultan proposed refining the traditional classification system for obstetric perineal lacerations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/5\">",
"     5",
"    </a>",
"    ]. The revised system provided a subclassification for third degree lacerations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       First degree lacerations",
"      </strong>",
"      involve injury to the perineal skin and vaginal epithelium only. The perineal muscles remain intact.",
"     </li>",
"     <li>",
"      <strong>",
"       Second degree lacerations",
"      </strong>",
"      extend into the fascia and musculature of the perineal body, which includes the deep and superficial transverse perineal muscles and fibers of the pubococcygeus and bulbocavernosus muscles. The anal sphincter muscles remain intact.",
"     </li>",
"     <li>",
"      <strong>",
"       Third degree lacerations",
"      </strong>",
"      extend through the fascia and musculature of the perineal body and involve some or all of the fibers of the EAS",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the IAS.",
"      <br/>",
"      <br/>",
"      Third degree lacerations are subclassified as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      3a: &lt;50 percent of EAS thickness is torn",
"     </li>",
"     <li>",
"      3b: &gt;50 percent of EAS thickness is torn",
"     </li>",
"     <li>",
"      3c: IAS is torn (in addition to complete rupture of the EAS)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Fourth degree lacerations",
"      </strong>",
"      involve the perineal structures, EAS, IAS, and the rectal mucosa.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above classification system represents a significant improvement over older systems, as it takes the IAS into account. It is not widely used clinically, but is described in the Royal College of Obstetricians and Gynaecologists&rsquo; guideline on management of third and fourth degree perineal tears [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key initial task is to assess both the extent of bleeding and injury to the perineum, vagina, and anorectum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/4\">",
"     4",
"    </a>",
"    ]. This assessment should include both visual inspection and palpation. Adequate exposure, lighting, and analgesia are essential for a thorough examination.",
"   </p>",
"   <p>",
"    Palpation is important to determine whether the rectal mucosa and anal sphincter are intact. The rectovaginal examination is accomplished by placing an index finger in the rectum and the thumb over the anal sphincter and using a pill-rolling motion to assess the sphincter. Of note, the anal sphincter may be disrupted by shearing forces produced by descent of the fetal head, and this can occur in women with an otherwise intact perineum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The surgeon should also make sure that the uterus is properly contracted following the delivery of the placenta. Although delivery of the placenta is not mandatory before beginning the repair, sutures can be disrupted by manual removal of the placenta and other intrauterine manipulations if such interventions become necessary after the perineum has been reapproximated.",
"   </p>",
"   <p>",
"    Lacerations can usually be repaired in the delivery room with the patient in the lithotomy position; third and fourth degree lacerations may require an operating room for ready access to appropriate equipment and lighting, and maintenance of aseptic conditions.",
"   </p>",
"   <p>",
"    If stool is obviously present, it should be removed and the tissues irrigated thoroughly. We perform a gentle scrub with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    under such conditions.",
"   </p>",
"   <p>",
"    Perineal shaving is unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1697096\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with third and fourth degree tears, the Royal College of Obstetricians and Gynaecologists suggests use of broad spectrum antibiotics to reduce the incidence of postoperative infection, which could result in wound dehiscence and, in turn, anal incontinence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/9\">",
"     9",
"    </a>",
"    ]. The value of pre- and post-operative antibiotics in this setting is based primarily on clinical experience; the available data from a single randomized trial are of low quality (eg, high rate of loss to follow-up) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Antibiotics are probably unnecessary, as the rate of infection and wound breakdown following primary repair is extremely low. If there is gross fecal spillage into the wound, then local cleansing, irrigation, and a single dose of a broad spectrum cephalosporin are probably prudent and sufficient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1697103\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The level of anesthesia should be adequate for the surgical repair. If the patient had an epidural catheter placed for labor and delivery",
"    <span class=\"nowrap\">",
"     analgesia/anesthesia,",
"    </span>",
"    it can be used to provide anesthesia for the repair.",
"   </p>",
"   <p>",
"    For repair of third or fourth degree lacerations, re-dosing may be needed prior to beginning the surgical repair as additional muscle relaxation is often necessary to relax the contracted anal sphincter, retrieve the retracted ends, and bring them back together without tension. A bilateral pudendal block with or without a local field block, a saddle block, or general anesthesia are alternatives if there is no preexisting analgesia.",
"   </p>",
"   <p>",
"    For repair of first and second degree lacerations, pudendal nerve block or local field block is generally adequate if there is no preexisting anesthesia. In patients with adequate epidural anesthesia, local anesthesia has been used to reduce postpartum analgesia requirements, but a randomized trial found neither",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/38/7782?source=see_link\">",
"     ropivacaine",
"    </a>",
"    nor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    was more effective than saline in the first 24 hours after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40439?source=see_link\">",
"     \"Pudendal and paracervical block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CHOICE OF SUTURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of sutures for repair of perineal lacerations is largely one of personal preference. In most institutions, chromic catgut has been largely replaced by synthetic, delayed-absorbable materials, such as polyglactin 910 and polyglycolic acid, as use of chromic catgut appears to be associated with more postpartum discomfort [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. A systematic review of randomized trials concluded that, compared with catgut (plain, chromic, glycerol impregnated), standard absorbable synthetic suture for perineal repair following childbirth was associated with less pain in the first three days postpartum (OR 0.83, 95% CI 0.76-0.90), less need for analgesia in the first 10 days postpartum (OR 0.71, 95% CI 0.59-0.87), and less resuturing for dehiscence (OR 0.25, 95% CI 0.08-0.74), but no difference in long-term pain or dyspareunia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/15\">",
"     15",
"    </a>",
"    ]. However, the need for removal of unabsorbed synthetic suture material was almost twice as common; this problem is significantly diminished by using rapidly-absorbable synthetic sutures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/15\">",
"     15",
"    </a>",
"    ]. When catgut and glycerol-impregnated catgut were compared, results were similar for most outcomes, although the latter was associated with more short-term pain.",
"   </p>",
"   <p>",
"    Rapid absorption (average 42 days) or standard absorption (average 63 days) braided polyglactin 910 sutures and monofilament sutures (eg, poliglecaprone 25, glycomer 631) in a variety of sizes are usually readily available on most Labor and Delivery Units. In general, one should use the smallest diameter suture that has adequate tensile and knot strength for the task;",
"    <span class=\"nowrap\">",
"     2/0",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     3/0",
"    </span>",
"    sutures are suitable for soft tissue repair. Monofilament sutures may cause less tissue reaction than braided sutures, and thus may minimize discomfort and infection risk. However, this must be balanced against the significantly longer absorption time, and quicker loss of tensile strength that is characteristic of monofilament sutures. In general, the use of polyglactin 910 suture sizes",
"    <span class=\"nowrap\">",
"     2/0",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     3/0",
"    </span>",
"    is a reasonable choice for most routine repair of perineal and vaginal lacerations.",
"   </p>",
"   <p>",
"    Several case studies and one small randomized trial in Europe have suggested that skin adhesives could be used in place of sutures in the repair of some perineal lacerations [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. These agents are expensive and not all are widely available; further study is needed to determine the safety and efficacy of this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SURGICAL TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sutures described in the text represent the author's preferences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Third and fourth degree tears",
"    </span>",
"    &nbsp;&mdash;&nbsp;Third or fourth degree tears, if present, should be repaired first. To help with exposure, a vaginal pack can be used to prevent uterine bleeding from obscuring the surgical field and a self-retaining retractor, such as a Gelpie or Weitlander, is helpful if an assistant is not readily available. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38440?source=see_link\">",
"     \"Surgical instruments for gynecologic surgery\"",
"    </a>",
"    .)&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38633?source=see_link\">",
"     \"Pharmacologic management of pain during labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The aim of reconstructive surgery is to restore the continuity of both the external and internal anal sphincters [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, a thick perineal body and rectovaginal septum should be created to provide muscular and structural support in the thin area between the anterior anorectum and vagina. Proper reconstruction will also result in lengthening of the anal canal and restoration of a functional high pressure zone within it.",
"   </p>",
"   <p>",
"    The goal of sphincter repair (either primary or secondary) is reconstruction of a muscular cylinder that is at least 2 cm thick and 3 cm long [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/4,20\">",
"     4,20",
"    </a>",
"    ]. This results in an anatomically and functionally correct anal canal. Simple plication of the severed ends of the external anal sphincter with two or three interrupted, absorbable sutures is commonly performed, but may be inadequate since this approach is frequently associated with persistent sphincter defects and symptomatology [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/21\">",
"     21",
"    </a>",
"    ]. Meticulous hemostasis and anatomic reapproximation of all disrupted tissue layers are the key principles for preventing complications and restoring fecal competence.",
"   </p>",
"   <p>",
"    The optimal repair consists of a multilayer closure (",
"    <a class=\"graphic graphic_figure graphicRef66412 \" href=\"UTD.htm?20/31/20978\">",
"     figure 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      If a fourth degree laceration is present, we repair the torn anal mucosa using a continuous (nonlocking)",
"      <span class=\"nowrap\">",
"       3/0",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       4/0",
"      </span>",
"      polyglactin; a monofilament suture such as poliglecaprone 25 is also acceptable. Interrupted sutures can be used, but result in a larger quantity of foreign body because of multiple knots.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The internal anal sphincter should be properly identified and repaired as a separate layer [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/4,22\">",
"       4,22",
"      </a>",
"      ]. It often retracts laterally and superiorly and appears as thickened, pale pink, shiny tissue just above the anal mucosa that some clinicians refer to as perirectal fascia. Reapproximation of this layer is important for the strength and integrity of the repair and for achieving anal continence [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/23\">",
"       23",
"      </a>",
"      ]. We use a continuous",
"      <span class=\"nowrap\">",
"       3/0",
"      </span>",
"      polyglactin suture or",
"      <span class=\"nowrap\">",
"       3/0",
"      </span>",
"      monofilament synthetic suture (eg, poliglecaprone 25) on a gastrointestinal needle for this repair.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The external sphincter is then identified and repaired. The repair begins by identifying and grasping the two severed ends of the dark red external anal sphincter muscle with Allis clamps. It may be necessary to push the Allis clamp deep into the surrounding connective tissue to locate the sphincter since one or both ends typically retract when it ruptures.",
"     </li>",
"     <li>",
"      The repair consists of either an end-to-end or overlapping plication of the disrupted external anal sphincter and its capsule using interrupted or figure-of-eight sutures;",
"      <span class=\"nowrap\">",
"       2/0",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       3/0",
"      </span>",
"      polydioxanone or",
"      <span class=\"nowrap\">",
"       2/0",
"      </span>",
"      polyglactin suture on a cut tapered 1 or 2 needle are reasonable suture choices. We recommend not using chromic suture for repair of the anal sphincter.",
"      <br/>",
"      <br/>",
"      We typically place at least four or five interrupted sutures, but we are not opposed to placing more if it is possible. It may be necessary to sharply mobilize either sphincter end to achieve a better anastomosis and minimize tension.",
"      <br/>",
"      <br/>",
"      A meta-analysis (3 trials involving 279 women) concluded the overlap technique might be associated with a lower risk of fecal urgency and a lower mean anal incontinence score at 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/24\">",
"       24",
"      </a>",
"      ], but these results were limited to one small trial [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/25\">",
"       25",
"      </a>",
"      ]. There were no significant differences between procedures in perineal pain, dyspareunia, incontinence of flatus or feces, or quality of life at 6 weeks, 3 months, 6 months, and 12 months after repair. Limitations of these trials were the inclusion of multiparous women and women with partial tears, and differences in measurement of outcomes and surgical experience.",
"      <br/>",
"      <br/>",
"      Subsequent to this meta-analysis, a randomized trial of the overlap and end-to-end techniques limited to primiparous women with complete tears reported that at 6 and 12 months postpartum the overlap technique was associated with a higher rate of flatal incontinence (6 months: 61 versus 39 percent, P=.005; 12 months: 56 versus 31 percent, P=0.12) and a trend toward a higher rate of fecal incontinence (6 months: 15 versus 8 percent, P&gt;.2; 12 months 16 versus 6 percent, P=.17) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/26\">",
"       26",
"      </a>",
"      ]. Another randomized trial of the two techniques in primiparous and multiparous women with either partial or complete tears found the overlap repair was not superior to the end-to-end technique with respect to fecal incontinence at 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/27\">",
"       27",
"      </a>",
"      ]. Others have observed that the incidence of residual anal sphincter damage on endoanal ultrasonography is similar for the two techniques [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/3,27\">",
"       3,27",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In the absence of clear evidence favoring one technique over the other, the choice of overlap or end-to-end repair should be based on the surgeon&rsquo;s preference and experience.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After the sphincter repair is completed, the next task is to rebuild the distal rectovaginal septum and perineal body. This layer helps to maintain the proper spatial distance between the anus and vagina, and may prevent suture erosion from the deeper layers. Another goal of this layer is to help take the tension off of the underlying sphincter repair. We typically use an interrupted",
"    <span class=\"nowrap\">",
"     2/0",
"    </span>",
"    polyglactin suture on a cutting needle.",
"   </p>",
"   <p>",
"    The end result of the surgical repair should be reconstruction of an adequate perineal body, a thickened rectovaginal septum, and an intact cylindrical sphincter complex that is approximately 2 cm wide and 3 cm long. The anus should easily admit one finger following the procedure, although skeletal muscle paralysis induced by anesthesia may temporarily weaken the tone of the anal canal.",
"   </p>",
"   <p>",
"    The remainder of the repair is as described below for first and second degree tears (",
"    <a class=\"graphic graphic_figure graphicRef75126 \" href=\"UTD.htm?38/59/39857\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     First and second degree tears",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is no third or fourth degree extension, the perineum has traditionally been repaired in three stages using a single continuous non-locking suture technique beginning at the apex of the vaginal laceration and ending with a subcuticular layer culminating at the level of the fourchette.",
"   </p>",
"   <p>",
"    Continuous non-locking suture techniques for repair of the vagina, perineal muscles, and skin appear to be preferable to traditional interrupted methods. The continuous technique is faster and uses the smallest amount of suture material; the only advantage of an intermittent technique is that if one suture breaks, there are others to hold the repair in place; however, this is probably not critical in the perineum. Meta-analysis of randomized trials of continuous versus interrupted suture techniques for perineal closure found that the continuous suturing technique was associated with [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/28\">",
"     28",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Less pain for up to 10 days postpartum (RR 0.76, 95% CI 0.66-0.88; nine trials), especially when used for all layers.",
"     </li>",
"     <li>",
"      Less need for analgesia for up to 10 days postpartum (RR 0.70, 95% CI 0.59-0.84).",
"     </li>",
"     <li>",
"      Less need for suture removal (RR 0.56, 95% CI 0.32-0.98), but no significant differences in the need for resuturing of wounds or long-term pain.",
"     </li>",
"     <li>",
"      A trend in reduction of dyspareunia up to three months postpartum (RR 0.86, 95% CI 0.67-1.09)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The differences in pain between the two techniques may be due to increased suture tension with interrupted stitches, which may lead to edema and pain. With continuous sutures, the tension is transferred along the length of a single suture and the subcuticular layer is placed well below the skin surface, thus avoiding the nerve endings.",
"   </p>",
"   <p>",
"    The vaginal epithelium is reapproximated first, and should include any underlying divided tissue in order to build up the rectovaginal septum. Care should be taken to identify and incorporate the apex of the episiotomy in the repair. If the apex of the episiotomy extends out of the field of vision, a suture can be placed below the apex and the suture tail used as a purchase to pull the apex into view. An absorbable suture (typically a",
"    <span class=\"nowrap\">",
"     2/0",
"    </span>",
"    polyglactin 910) is usually used for the repair. The anatomical landmarks, such as the vermilion border and hymenal ring, should be identified and reapproximated. Theoretically, use of a locking stitch will prevent pulling the suture too tight and shortening the vagina; we do not use a locking stitch, as there is no evidence to support this theory.",
"   </p>",
"   <p>",
"    Following closure of the vaginal portion of the laceration down to the level of the hymenal ring, the perineal body and bulbocavernosus muscle are reapproximated. The same suture is usually passed through the vaginal layer above through to the deep perineal layer, in what is commonly referred to as the &ldquo;transition stitch.&rdquo; The suture is then placed through the superficial bulbocavernosus muscle on each side in a &ldquo;V&rdquo; configuration, commonly referred to as the \"crown\" stitch. Some surgeons prefer to close this layer in an interrupted manner.",
"   </p>",
"   <p>",
"    The suture is next passed through the deep perineal tissue from side to side in a vertical direction until the edge of the perineal tear is reached. At this point, the suture is brought back up along the perineal body in a subcuticular manner and tied at, or just inside, the introitus with a loop knot.",
"   </p>",
"   <p>",
"    Some authors have proposed leaving the perineal skin open, to heal by secondary intention, because avoiding suture material has been associated with better skin sensation when assessed one year postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/29\">",
"     29",
"    </a>",
"    ]. Two randomized trials attempted to evaluate whether suturing or nonsuturing of first and second degree perineal lacerations improved outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. There was a similar degree of postpartum discomfort with both approaches, but one study described better wound healing when subcuticular closure was performed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/31\">",
"     31",
"    </a>",
"    ]. A meta-analysis of the two trials concluded there was insufficient evidence to recommend surgical repair over nonsurgical management, and more data were needed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881188\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The comparative outcomes of women who undergo episiotomy and repair versus those who do not undergo episiotomy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13992?source=see_link&amp;anchor=H5#H5\">",
"     \"Approach to episiotomy\", section on 'Episiotomy versus no episiotomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6881257\">",
"    <span class=\"h2\">",
"     Third and fourth degree repairs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials comparing end-to-end and overlap techniques of external sphincter repair generally report that 60 to 80 percent of patients are asymptomatic at 12 months follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/21,25,33\">",
"     21,25,33",
"    </a>",
"    ]. Many of these women have persistent defects on endoanal ultrasound examination [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/3,34\">",
"     3,34",
"    </a>",
"    ]; the long-term significance of this finding is unknown. Symptomatic patients usually complain of incontinence of flatus or fecal urgency; leakage of stool is less common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MEDIOLATERAL EPISIOTOMY REPAIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repair of mediolateral episiotomies is approached by first reapproximating the transverse perineal and bulbocavernosus muscles. Larger suture bites should be taken on the lateral side of the incision because the two surfaces are unequal, with the lateral aspect having a larger area than the medial. The remainder of the repair is similar to that described above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SECONDARY REPAIR OF EPISIOTOMY BREAKDOWN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episiotomy infection and dehiscence are uncommon, but important postpartum complications. Signs of episiotomy infection include fever, wound tenderness, and purulent discharge, typically occurring six to eight days following delivery. A retrospective review of more than 7000 deliveries in which a median episiotomy was performed reported an 11.6 percent rate of third and fourth degree extensions that resulted in 0.1 percent incidence of rectovaginal fistulas, 0.1 percent incidence of episiotomy infection, and 29 percent incidence of poor sphincter tone [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Early versus delayed repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, secondary repair of episiotomy breakdown was deferred for a minimum of two to three months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/36\">",
"     36",
"    </a>",
"    ]. The purpose for delay was to allow sufficient time for revascularization of the wound edges and formation of scar tissue, which was thought to be of value during reanastomosis of the torn sphincter. However, few data support this approach and it commits the woman to an extended period of physical, social, and sexual disability because of continuous incontinence. Available evidence supports re-repair of both superficial and deep episiotomy dehiscence within the first two weeks following childbirth, which may result in a reduction in perineal pain during the healing process up to six months postdelivery and a reduction in dyspareunia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early repair of episiotomy breakdown has replaced the traditional approach and has overall success rates of 87 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/38-43\">",
"     38-43",
"    </a>",
"    ]. Disadvantages of an early procedure include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It prolongs hospitalization early in the postpartum period, which could interfere with breastfeeding and maternal-infant bonding.",
"     </li>",
"     <li>",
"      It removes the possibility of spontaneous closure, which could occur in some cases.",
"     </li>",
"     <li>",
"      Some early attempts at repair may fail, resulting in a need for subsequent surgical procedures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Wound care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The open wound should be inspected for evidence of bacterial overgrowth, exudate, necrotic tissue, and suture fragments. It should be d&eacute;brided at the bedside, using low pressure irrigation with warm isotonic (normal) saline, mechanical debridement, and sharp dissection, as needed. In some cases, transfer to an operating room and regional or local anesthesia may be necessary to remove nonviable tissue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=see_link\">",
"     \"Basic principles of wound management\"",
"    </a>",
"    .) Sitz baths are offered several times daily for patient comfort.",
"   </p>",
"   <p>",
"    Women with clinically-evident cellulitis should be treated with broad spectrum antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=see_link\">",
"     \"Cellulitis and erysipelas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early secondary repair is performed when the wound surface is free from exudate and covered by pink granulation tissue. If cellulitis was present, it should be resolved. On average, it will take six to eight days of aggressive wound care before the repair can be attempted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6880677\">",
"    <span class=\"h2\">",
"     Preoperative preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with superficial disruption of a first or second degree laceration, some surgeons give a single preoperative dose of a broad spectrum antibiotic, such as a cephalosporin. The value of antibiotics in this setting has not been studied in randomized trials.",
"   </p>",
"   <p>",
"    There is no evidence on which to base a recommendation for a preoperative bowel regimen before anal surgery. In secondary closures that involve re-repair of the anal sphincter",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rectal mucosa, we feel the use of an enema the night before surgery to remove the potential for perioperative fecal contamination is sufficient preparation of the lower colon and anorectum. The use of a mechanical bowel prep is unnecessary. An antibiotic regimen that covers skin and enteric flora is also administered preoperatively. Appropriate regimens for patients with and without beta-lactam allergy, as well as the evidence behind these recommendations, can be found separately (",
"    <a class=\"graphic graphic_table graphicRef65369 \" href=\"UTD.htm?23/52/24397\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18806?source=see_link&amp;anchor=H1191970282#H1191970282\">",
"     \"Control measures to prevent surgical site infection following gastrointestinal procedures\", section on 'Colorectal surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6880684\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary repair is performed in the same way as the primary",
"    <span class=\"nowrap\">",
"     episiotomy/perineal",
"    </span>",
"    laceration repair described above. Some surgeons use interrupted, rather than continuous, sutures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of evidence-based information regarding care of the perineum after childbirth, with or without episiotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Good perineal hygiene and elevation of the foot of the bed if there is perineal edema may be useful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39402?source=see_link&amp;anchor=H183548616#H183548616\">",
"     \"Overview of postpartum care\", section on 'Perineal care'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, the diet prescribed for the first 30 postoperative days is a matter of personal preference. We suggest a low residue diet for our patients who undergo third or fourth degree laceration repair to reduce stool volume and frequency. Others prefer a high fiber diet, which will produce voluminous, but soft stools. A stool softener is commonly prescribed in either case for 10 days or more postpartum. Some authors have suggested using an osmotic laxative, such as milk of magnesia or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    postpartum, as well, for up to 10 days postpartum [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/9,46,47\">",
"     9,46,47",
"    </a>",
"    ]. The use of fiber supplements should be avoided, as they tend to be associated with an increased incidence of incontinent episodes.",
"   </p>",
"   <p>",
"    We suggest nonsteroidal antiinflammatory drugs for analgesia because of their effectiveness, low cost, low incidence of side effects, and ease of administration. Topical",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ointment is no longer routinely used following episiotomy, as several reports have shown that topically-applied anesthetics were no more effective than placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3433/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence to support routine use of prophylactic antibiotics following the primary repair of an episiotomy or laceration, including third and fourth degree lacerations, and it should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276282795\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF FUTURE DELIVERIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of future deliveries after repair of a third or fourth degree laceration is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=see_link&amp;anchor=H25#H25\">",
"     \"Fecal incontinence related to pregnancy and vaginal delivery\", section on 'Approach to obstetric management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/0/22529?source=see_link\">",
"       \"Patient information: Maternal injuries from childbirth (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Occult injury to the anal sphincter occurs frequently at the time of vaginal delivery and can contribute to anal incontinence. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initially, the key task is to examine the perineum and vagina thoroughly to determine the extent of injury and severity of bleeding. This assessment should include a rectovaginal examination of the anal sphincter complex and rectal mucosa. Unrecognized injury to the anal sphincter complex is common after vaginal delivery. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Preoperative preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The anal sphincter can be disrupted even though the perineum is intact. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The aim of reconstructive surgery is to restore the continuity of both the external and internal anal sphincters and create a thick perineal body and rectovaginal septum. Reapproximation of the internal sphincter is important for the strength and integrity of the repair and for achieving anal continence. Proper reconstruction will lengthen the anal canal and the functional high pressure zone within it. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Third and fourth degree tears'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is unclear whether an overlapping repair yields better long-term results than a traditional end-to-end repair. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Third and fourth degree tears'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, early re-repair of an episiotomy breakdown is desirable to minimize both short-term and long-term perineal pain. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Early versus delayed repair'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/1\">",
"      Bols EM, Hendriks EJ, Berghmans BC, et al. A systematic review of etiological factors for postpartum fecal incontinence. Acta Obstet Gynecol Scand 2010; 89:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/2\">",
"      Sultan AH, Kamm MA, Hudson CN, et al. Anal-sphincter disruption during vaginal delivery. N Engl J Med 1993; 329:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/3\">",
"      Dudding TC, Vaizey CJ, Kamm MA. Obstetric anal sphincter injury: incidence, risk factors, and management. Ann Surg 2008; 247:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/4\">",
"      Delancey JO, Toglia MR, Perucchini D. Internal and external anal sphincter anatomy as it relates to midline obstetric lacerations. Obstet Gynecol 1997; 90:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/5\">",
"      Sultan, AH. Obstetric perineal injury and anal incontinence (editorial). Clin Risk 1999; 5:193.",
"     </a>",
"    </li>",
"    <li>",
"     RCOG. Management of third and fourth degree perineal tears. Green-top guideline no. 29. March 2007. www.rcog.org.uk/files/rcog-corp/GTG2911022011.pdf (Accessed on May 08, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/7\">",
"      Frudinger A, Bartram CI, Spencer JA, Kamm MA. Perineal examination as a predictor of underlying external anal sphincter damage. Br J Obstet Gynaecol 1997; 104:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/8\">",
"      Basevi V, Lavender T. Routine perineal shaving on admission in labour. Cochrane Database Syst Rev 2001; :CD001236.",
"     </a>",
"    </li>",
"    <li>",
"     Royal College of Obstetricians and Gynaecologists. The management of third- and fourth-degree perineal tears. Green-top guideline No. 29, March 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/10\">",
"      Duggal N, Mercado C, Daniels K, et al. Antibiotic prophylaxis for prevention of postpartum perineal wound complications: a randomized controlled trial. Obstet Gynecol 2008; 111:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/11\">",
"      Buppasiri P, Lumbiganon P, Thinkhamrop J, Thinkhamrop B. Antibiotic prophylaxis for third- and fourth-degree perineal tear during vaginal birth. Cochrane Database Syst Rev 2010; :CD005125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/12\">",
"      Schinkel N, Colbus L, Soltner C, et al. Perineal infiltration with lidocaine 1%, ropivacaine 0.75%, or placebo for episiotomy repair in parturients who received epidural labor analgesia: a double-blind randomized study. Int J Obstet Anesth 2010; 19:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/13\">",
"      Mackrodt C, Gordon B, Fern E, et al. The Ipswich Childbirth Study: 2. A randomised comparison of polyglactin 910 with chromic catgut for postpartum perineal repair. Br J Obstet Gynaecol 1998; 105:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/14\">",
"      Greenberg JA, Lieberman E, Cohen AP, Ecker JL. Randomized comparison of chromic versus fast-absorbing polyglactin 910 for postpartum perineal repair. Obstet Gynecol 2004; 103:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/15\">",
"      Kettle C, Dowswell T, Ismail KM. Absorbable suture materials for primary repair of episiotomy and second degree tears. Cochrane Database Syst Rev 2010; :CD000006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/16\">",
"      Mota R, Costa F, Amaral A, et al. Skin adhesive versus subcuticular suture for perineal skin repair after episiotomy--a randomized controlled trial. Acta Obstet Gynecol Scand 2009; 88:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/17\">",
"      Bowen ML, Selinger M. Episiotomy closure comparing enbucrilate tissue adhesive with conventional sutures. Int J Gynaecol Obstet 2002; 78:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/18\">",
"      Rogerson L, Mason GC, Roberts AC. Preliminary experience with twenty perineal repairs using Indermil tissue adhesive. Eur J Obstet Gynecol Reprod Biol 2000; 88:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/19\">",
"      Adoni A, Anteby E. The use of Histoacryl for episiotomy repair. Br J Obstet Gynaecol 1991; 98:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/20\">",
"      Aronson MP, Lee RA, Berquist TH. Anatomy of anal sphincters and related structures in continent women studied with magnetic resonance imaging. Obstet Gynecol 1990; 76:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/21\">",
"      Malouf AJ, Norton CS, Engel AF, et al. Long-term results of overlapping anterior anal-sphincter repair for obstetric trauma. Lancet 2000; 355:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/22\">",
"      Lindqvist PG, Jernetz M. A modified surgical approach to women with obstetric anal sphincter tears by separate suturing of external and internal anal sphincter. A modified approach to obstetric anal sphincter injury. BMC Pregnancy Childbirth 2010; 10:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/23\">",
"      Mahony R, Behan M, Daly L, et al. Internal anal sphincter defect influences continence outcome following obstetric anal sphincter injury. Am J Obstet Gynecol 2007; 196:217.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/24\">",
"      Fernando R, Sultan AH, Kettle C, et al. Methods of repair for obstetric anal sphincter injury. Cochrane Database Syst Rev 2006; :CD002866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/25\">",
"      Fernando RJ, Sultan AH, Kettle C, et al. Repair techniques for obstetric anal sphincter injuries: a randomized controlled trial. Obstet Gynecol 2006; 107:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/26\">",
"      Farrell SA, Flowerdew G, Gilmour D, et al. Overlapping compared with end-to-end repair of complete third-degree or fourth-degree obstetric tears: three-year follow-up of a randomized controlled trial. Obstet Gynecol 2012; 120:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/27\">",
"      Rygh AB, K&ouml;rner H. The overlap technique versus end-to-end approximation technique for primary repair of obstetric anal sphincter rupture: a randomized controlled study. Acta Obstet Gynecol Scand 2010; 89:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/28\">",
"      Kettle C, Dowswell T, Ismail KM. Continuous and interrupted suturing techniques for repair of episiotomy or second-degree tears. Cochrane Database Syst Rev 2012; 11:CD000947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/29\">",
"      Grant A, Gordon B, Mackrodat C, et al. The Ipswich childbirth study: one year follow up of alternative methods used in perineal repair. BJOG 2001; 108:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/30\">",
"      Lundquist M, Olsson A, Nissen E, Norman M. Is it necessary to suture all lacerations after a vaginal delivery? Birth 2000; 27:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/31\">",
"      Fleming VE, Hagen S, Niven C. Does perineal suturing make a difference? The SUNS trial. BJOG 2003; 110:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/32\">",
"      Elharmeel SM, Chaudhary Y, Tan S, et al. Surgical repair of spontaneous perineal tears that occur during childbirth versus no intervention. Cochrane Database Syst Rev 2011; :CD008534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/33\">",
"      Williams A, Adams EJ, Tincello DG, et al. How to repair an anal sphincter injury after vaginal delivery: results of a randomised controlled trial. BJOG 2006; 113:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/34\">",
"      Fitzpatrick M, Behan M, O'Connell PR, O'Herlihy C. A randomized clinical trial comparing primary overlap with approximation repair of third-degree obstetric tears. Am J Obstet Gynecol 2000; 183:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/35\">",
"      Harris RE. An evaluation of the median episiotomy. Am J Obstet Gynecol 1970; 106:660.",
"     </a>",
"    </li>",
"    <li>",
"     Thompson, JD. Relaxed vaginal outlet, rectocele, fecal incontinence, and rectovaginal fistula. p. 941. In Thompson JD, Rock JA (eds): TeLinde's Operative Gynecology. 7th Ed. JB Lippincott, Philadelphia, 1992.",
"    </li>",
"    <li>",
"     Dudley LM, Kettle C, Ismail KMK. Secondary suturing compared to non-suturing for broken down perineal wounds following childbirth (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 2. Art. No.: CD008977. file://onlinelibrary.wiley.com/o/cochrane/clsysrev/articles/CD008977/frame.html (Accessed on August 03, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/38\">",
"      Ramin SM, Gilstrap LC 3rd. Episiotomy and early repair of dehiscence. Clin Obstet Gynecol 1994; 37:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/39\">",
"      Hankins GD, Hauth JC, Gilstrap LC 3rd, et al. Early repair of episiotomy dehiscence. Obstet Gynecol 1990; 75:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/40\">",
"      Hauth JC, Gilstrap LC 3rd, Ward SC, Hankins GD. Early repair of an external sphincter ani muscle and rectal mucosal dehiscence. Obstet Gynecol 1986; 67:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/41\">",
"      Monberg J, Hammen S. Ruptured episiotomia resutured primarily. Acta Obstet Gynecol Scand 1987; 66:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/42\">",
"      Ramin SM, Ramus RM, Little BB, Gilstrap LC 3rd. Early repair of episiotomy dehiscence associated with infection. Am J Obstet Gynecol 1992; 167:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/43\">",
"      Arona AJ, al-Marayati L, Grimes DA, Ballard CA. Early secondary repair of third- and fourth-degree perineal lacerations after outpatient wound preparation. Obstet Gynecol 1995; 86:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/44\">",
"      Chiarelli P, Cockburn J. Postpartum perineal management and best practice. Aust Coll Midwives Inc J 1999; 12:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/45\">",
"      Kettle C, Tohill S. Perineal care. Clin Evid (Online) 2011; 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/46\">",
"      Rosenberg J, Kehlet H. Early discharge after external anal sphincter repair. Dis Colon Rectum 1999; 42:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/47\">",
"      Mahony R, Behan M, O'Herlihy C, O'Connell PR. Randomized, clinical trial of bowel confinement vs. laxative use after primary repair of a third-degree obstetric anal sphincter tear. Dis Colon Rectum 2004; 47:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/48\">",
"      Minassian VA, Jazayeri A, Prien SD, et al. Randomized trial of lidocaine ointment versus placebo for the treatment of postpartum perineal pain. Obstet Gynecol 2002; 100:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3433/abstract/49\">",
"      Hedayati H, Parsons J, Crowther CA. Topically applied anaesthetics for treating perineal pain after childbirth. Cochrane Database Syst Rev 2005; :CD004223.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5399 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-EF0CD76C64-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_22_3433=[""].join("\n");
var outline_f3_22_3433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1697096\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1697103\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CHOICE OF SUTURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SURGICAL TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Third and fourth degree tears",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      First and second degree tears",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6881188\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6881257\">",
"      Third and fourth degree repairs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MEDIOLATERAL EPISIOTOMY REPAIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SECONDARY REPAIR OF EPISIOTOMY BREAKDOWN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Early versus delayed repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Wound care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6880677\">",
"      Preoperative preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6880684\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H276282795\">",
"      MANAGEMENT OF FUTURE DELIVERIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/5399\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5399|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/63/32756\" title=\"figure 1\">",
"      Female pelvic muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/57/29588\" title=\"figure 2\">",
"      Female perineum muscles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/30/14819\" title=\"figure 3\">",
"      Anatomy of the anus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/31/20978\" title=\"figure 4\">",
"      Repair of 4th degree laceration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/59/39857\" title=\"figure 5\">",
"      Repair median episiotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/5399|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/52/24397\" title=\"table 1\">",
"      Antimicrobial prophylaxis for gastrointestinal surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13992?source=related_link\">",
"      Approach to episiotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/63/27642?source=related_link\">",
"      Basic principles of wound management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12825?source=related_link\">",
"      Cellulitis and erysipelas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18806?source=related_link\">",
"      Control measures to prevent surgical site infection following gastrointestinal procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44071?source=related_link\">",
"      Evaluation and management of lower genital tract trauma in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=related_link\">",
"      Fecal incontinence related to pregnancy and vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39402?source=related_link\">",
"      Overview of postpartum care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/0/22529?source=related_link\">",
"      Patient information: Maternal injuries from childbirth (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/46/38633?source=related_link\">",
"      Pharmacologic management of pain during labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40439?source=related_link\">",
"      Pudendal and paracervical block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38440?source=related_link\">",
"      Surgical instruments for gynecologic surgery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_22_3434="Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome";
var content_f3_22_3434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, diagnosis, and treatment of the Budd-Chiari syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/22/3434/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3434/contributors\">",
"     Stephen C Hauser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/22/3434/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3434/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/22/3434/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/22/3434/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/22/3434/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Budd-Chiari syndrome can be defined as any pathophysiologic process that results in interruption or diminution of the normal blood flow out of the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/1\">",
"     1",
"    </a>",
"    ]. As commonly used, however, the Budd-Chiari syndrome implies thrombosis of the hepatic veins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the intrahepatic or suprahepatic inferior vena cava, although alternative nomenclature has been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations, diagnosis, and treatment of Budd-Chiari syndrome will be reviewed here. As will be discussed, there are no large controlled trials to guide therapy in patients with Budd-Chiari syndrome. Recommendations are derived mainly from retrospective studies and clinical experience. Treatment depends upon the cause, the anatomic location, and extent of the thrombotic process, and the condition of the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In addition, experience at individual centers may influence the choice of therapy. The etiology of Budd-Chiari syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=see_link\">",
"     \"Etiology of the Budd-Chiari syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Budd-Chiari syndrome is more common in women, and usually presents in the third or fourth decade, although it may occur in children or the elderly [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/5\">",
"     5",
"    </a>",
"    ]. One of the largest published series included a total of 237 patients who had been treated at four centers (in the United States, the Netherlands, and France) between 1984 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/6\">",
"     6",
"    </a>",
"    ]. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The median age was 35 (range 13 to 76)",
"     </li>",
"     <li>",
"      67 percent were female",
"     </li>",
"     <li>",
"      An overt myeloproliferative disorder was present in 23 percent (the majority of whom had polycythemia vera)",
"     </li>",
"     <li>",
"      The two most common symptoms were ascites (84 percent) and hepatomegaly (76 percent); 11 patients (5 percent) were asymptomatic",
"     </li>",
"     <li>",
"      The hepatic outflow obstruction was in the hepatic veins (62 percent) inferior vena cava (7 percent) or both (31 percent); 34 patients (14 percent) had associated portal vein thrombosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although there is variability in how patients present, presentation can generally be categorized as acute (and perhaps fulminant), subacute, or chronic. In one series of 44 patients, the following frequency of presentations was noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute &ndash; 20 percent (five with fulminant hepatic failure)",
"     </li>",
"     <li>",
"      Subacute (having signs or symptoms for less than six months and no evidence of liver cirrhosis) &ndash; 40 percent",
"     </li>",
"     <li>",
"      Chronic (having signs or symptoms for more than six months with evidence of portal hypertension and cirrhosis) &ndash; 40 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another report of 163 patients, the disease was categorized as acute (26 percent), chronic (20 percent), or both (50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/7\">",
"     7",
"    </a>",
"    ]. Acute was defined as the presence of abdominal pain, an alanine aminotransferase (ALT) level &gt;5 times the upper limit of normal, and liver cell loss at biopsy (if available). Chronic was defined as previous symptoms or hospitalizations, splenomegaly, atrophy or hypertrophy complex of liver lobes, and centrilobular fibrosis or cirrhosis on biopsy. Symptoms were present for less than one month, one to six months, or more than six months in 50, 34, and 1 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute disease occurs most commonly in women. It may be encountered during pregnancy when physiologic changes can unmask an underlying clotting disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/8\">",
"     8",
"    </a>",
"    ]. Patients usually present with severe right upper quadrant pain and hepatomegaly. Jaundice and ascites may not be apparent initially, but often develop rapidly. Ascites is detectable by ultrasound in more than 90 percent of patients. Variceal bleeding may also occur.",
"   </p>",
"   <p>",
"    Biochemical tests of liver function are abnormal, although the magnitude and pattern of abnormalities can vary. Elevation of serum aminotransferases reflects the vascular congestion and resulting ischemic hepatocellular damage. Serum aminotransferase concentrations can range from 100 to 200 int.",
"    <span class=\"nowrap\">",
"     unit/L",
"    </span>",
"    to more than 600 int.",
"    <span class=\"nowrap\">",
"     unit/L.",
"    </span>",
"    One study of 96 consecutive patients with Budd-Chiari syndrome found that high levels of ALT (&ge;5 times the upper limit of normal) reflected acute, severe but potentially reversible ischemic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/9\">",
"     9",
"    </a>",
"    ]. The authors also noted that a slow decline in ALT levels (&lt;50 percent of starting concentration within three days) predicted a poor outcome.",
"   </p>",
"   <p>",
"    The serum alkaline phosphatase is often in the range of 300 to 400 int.",
"    <span class=\"nowrap\">",
"     unit/L.",
"    </span>",
"    Serum bilirubin levels are usually less than 7",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    upon presentation, but may continue to rise. Liver function can deteriorate quickly, leading to hepatic encephalopathy and liver failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute form of Budd-Chiari syndrome may share features with other causes of fulminant hepatic failure, including ischemic, viral,",
"    <span class=\"nowrap\">",
"     malignant/infiltrative,",
"    </span>",
"    and toxic hepatitis, although serum aminotransferases are usually not as elevated. (See appropriate topic reviews.) It should also be considered in the differential diagnosis of patients with suspected veno-occlusive disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Subacute and chronic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The subacute and chronic forms of Budd-Chiari syndrome have been present for several weeks to more than six months prior to clinical presentation. The clinical manifestations and duration of disease prior to presentation depend upon the particular vessels that are occluded, the extent of occlusion, and the recruitment of collateral circulation.",
"   </p>",
"   <p>",
"    Patients with incomplete or partial occlusion of the hepatic veins, for example, may remain asymptomatic or minimally symptomatic until the disease progresses [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/10\">",
"     10",
"    </a>",
"    ]. Patients may recall vague discomfort related to the mid epigastrium or right upper quadrant.",
"   </p>",
"   <p>",
"    Chronic occlusion of the hepatic veins may be associated with hypertrophy of the caudate lobe of the liver, which receives a separate blood supply from the rest of the liver. The hypertrophied caudate lobe can eventually cause compression of the intrahepatic portion of the inferior vena cava, leading to further outflow obstruction, accompanied by the development of ascites and lower extremity edema (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef57838 \" href=\"UTD.htm?41/63/43006\">",
"     image 1",
"    </a>",
"    ). Simultaneously, cirrhosis may have developed in the chronically congested liver, resulting in portal hypertension and the development of varices and other stigmata of portal hypertension. Patients may then develop ascites, which may be massive. Hepatomegaly and abdominal pain are also common. In contrast to the acute form of Budd-Chiari syndrome, encephalopathy is infrequent. Hepatopulmonary syndrome has been described in up to 28 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3640?source=see_link\">",
"     \"Hepatopulmonary syndrome: Prevalence, causes, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The subacute and chronic forms of Budd-Chiari syndrome may present with normal or mild to moderate elevation of serum aminotransferases, alkaline phosphatase, and serum bilirubin, hypoalbuminemia, and hypoprothrombinemia. Jaundice is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation in the chronic and subacute forms of Budd-Chiari is similar to that accompanying cirrhosis or portal hypertension of any cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=see_link\">",
"     \"Diagnostic approach to the patient with cirrhosis\"",
"    </a>",
"    .) The hepatomegaly and abnormal serum biochemistries in Budd-Chiari syndrome may also be seen in patients with right-sided heart failure. Ascitic fluid protein concentration may be greater than 3.0",
"    <span class=\"nowrap\">",
"     g/L,",
"    </span>",
"    with a serum-ascites albumin concentration gradient greater than 1.1",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    similar to that in patients with cardiac and pericardial disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic or subacute Budd-Chiari syndrome should be considered in the differential diagnosis of otherwise unexplained liver dysfunction, particularly in patients in whom ascites is a principal feature, or in those who have a known risk factor for Budd-Chiari syndrome (",
"    <a class=\"graphic graphic_table graphicRef79884 \" href=\"UTD.htm?39/22/40299\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=see_link\">",
"     \"Etiology of the Budd-Chiari syndrome\"",
"    </a>",
"    .) The acute form of the disease should be suspected in patients presenting with acute hepatic failure associated with hepatomegaly, right upper quadrant pain, and ascites, and in the differential diagnosis of patients with veno-occlusive disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=see_link\">",
"     \"Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation\"",
"    </a>",
"    .) The diagnosis can be established noninvasively by ultrasonography with Doppler studies, CT scan, or magnetic resonance angiography (MRI angiography). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28054?source=see_link\">",
"     \"Magnetic resonance imaging of the hepatobiliary tract\"",
"    </a>",
"    .) The accuracy of noninvasive imaging modalities depends upon the clinical characteristics, duration of disease, and the location of the clot. The portal and splenic circulation should also be evaluated to exclude concurrent thrombosis. Occlusion of the portal vein in patients with Budd-Chiari syndrome limits therapeutic options and has a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Splenomegaly is uncommon, but may be found on physical examination in up to 30 percent of patients, and venous collaterals may be seen on the anterior abdominal wall. Edema of the lower extremities and the presence of venous collaterals on the back suggest occlusion of the inferior vena cava. Signs of right-sided congestive heart failure (such as jugular venous distension) are not characteristic of Budd-Chiari syndrome, and may suggest an underlying cardiac cause of fluid accumulation.",
"   </p>",
"   <p>",
"    Ascitic fluid in patients with Budd-Chiari syndrome has a high serum to ascites protein gradient (&gt;1.1), reflecting the elevated portal pressures. The protein concentration is variable (ranging from 1.5 to 4.9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in one report) and is directly related to the serum protein and inversely related to portal pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=see_link\">",
"     \"Evaluation of adults with ascites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Doppler ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler ultrasonography is the most useful noninvasive diagnostic test to screen for the presence of Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/14\">",
"     14",
"    </a>",
"    ]. Nonspecific findings on ultrasound include hepatomegaly, splenomegaly, ascites, intraabdominal collaterals, caudate lobe hypertrophy, atrophy of other hepatic lobes, and compression or narrowing of the inferior vena cava. More specific findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inability to visualize the junction of the major hepatic veins with the inferior vena cava",
"     </li>",
"     <li>",
"      Thickening, irregularity, stenosis, or dilation of the walls of the hepatic veins",
"     </li>",
"     <li>",
"      Abnormal flow in the major hepatic veins or inferior vena cava, which is best demonstrated during color Doppler studies",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     CT scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT scanning may reveal the same nonspecific abnormalities seen during ultrasonography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77769 \" href=\"UTD.htm?5/47/5874\">",
"     image 2",
"    </a>",
"    ). In addition, more specific findings on CT scan that suggest the Budd-Chiari syndrome include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delayed or absent filling of the three major hepatic veins (which are usually visible within 40 to 60 seconds after rapid intravenous contrast)",
"     </li>",
"     <li>",
"      A peculiar, patchy flea-bitten appearance of the liver due to increased central relative to peripheral contrast enhancement. This pattern reverses and produces inhomogeneous parenchymal opacification",
"     </li>",
"     <li>",
"      Rapid clearance of dye from the caudate lobe",
"     </li>",
"     <li>",
"      Narrowing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      lack of opacification of the inferior vena cava",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging may be of great use in the diagnosis of Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In addition to the nonspecific findings described above, the absence or reduction in caliber of hepatic veins and the typical distorted \"comma-shaped\" intrahepatic collaterals are easily demonstrable. A newer approach, three-dimensional contrast-enhanced magnetic resonance venography, is proving to be helpful in diagnosis of pathology of the vena cava including Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/17\">",
"     17",
"    </a>",
"    ]. However, it is not yet widely available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sulfur-colloid scintigraphy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfur-colloid scintigraphy can also suggest the diagnosis. Although frequently performed in the past, it has generally been replaced by these other imaging modalities. Hypertrophy of the caudate lobe associated with Budd-Chiari syndrome is demonstrated by its preferential uptake of the radionuclide. However, more than half of patients with the Budd-Chiari syndrome do not demonstrate this pattern, probably due to the variable extent of the thrombotic process in the hepatic veins [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Venography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gold standard for diagnosis is venography, which is performed by accessing the hepatic venous circulation percutaneously, either via the internal jugular vein, cephalic vein, or femoral vein. Venography should be performed if noninvasive tests are negative or nondiagnostic but there is strong clinical suspicion for the disease.",
"   </p>",
"   <p>",
"    Venous pressure measurements should be recorded above and below the entrance of the hepatic veins into the inferior vena cava to determine whether a significant pressure gradient exists. Once the inferior vena cava has been shown to be patent, opacification of each of the individual hepatic veins should be attempted. However, venography of some or all of the hepatic veins may not be feasible in many patients with the Budd-Chiari syndrome. Injection of contrast following balloon occlusion of a specific hepatic vein may facilitate its visualization and also demonstrate the so-called \"spider web\" pattern characteristic of the Budd-Chiari syndrome. This pattern depicts the futile attempt of the liver to form venous collaterals to bypass the occluded hepatic veins.",
"   </p>",
"   <p>",
"    Venography can be critical for deciding upon optimal therapy. Noninvasive studies may not accurately define the extent or characteristics of the hepatic venous flow. In particular, compression or occlusion of the intrahepatic vena cava, leads to sluggish flow in hepatic veins. As a result, the hepatic veins can be undetectable during ultrasound Doppler studies, although they may be patent and amenable to therapy. MRI venography can be helpful in better defining the venous anatomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Arteriography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral arteriography is mandatory when planning a surgical approach to decompress the congested liver. The hepatic arteries are usually stretched, arched, and attenuated, which may possibly influence the surgical approach. In addition, the patency of the portal, splenic, and mesenteric veins can be determined and tumors involving the liver, inferior vena cava, or the hepatic and portal veins can be identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of noninvasive diagnostic tests depends upon the suspicion for the disease, and the available expertise. We usually begin with Doppler ultrasonography. In patients with an unremarkable ultrasound examination but in whom the suspicion for Budd-Chiari is high, magnetic resonance imaging is a reasonable next option. Venography can be used to confirm the diagnosis and to plan therapeutic interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Liver biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A liver biopsy can be diagnostic of Budd-Chiari syndrome, particularly in the acute or subacute form of the disease. Histologic features include centrizonal congestion, necrosis, and hemorrhage. Large regenerative nodules and obstructive portal venopathy may also be found [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/18\">",
"     18",
"    </a>",
"    ]. Cirrhosis may be present in the chronic form of the disease.",
"   </p>",
"   <p>",
"    A liver biopsy can also be helpful for determining prognosis and for guiding therapy. Patients who have already developed cirrhosis, for example, are less likely to benefit from revascularization procedures compared to those who have predominant features of hepatic congestion, but have not yet developed scarring. On the other hand, one study suggested that histologic findings at the time of diagnosis did not predict five-year survival, although there was a trend to decreased survival among those with central vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is often practical to obtain a liver biopsy via the transjugular route during performance of hepatic venography, since the majority of patients have ascites, which increases the risk of the percutaneous approach. However, a percutaneous biopsy can be performed in the absence of or after treatment of ascites, if coagulation parameters permit.",
"   </p>",
"   <p>",
"    It should be remembered that the thrombotic process in Budd-Chiari syndrome may not involve all the hepatic veins. Thus, the distribution of the typical pathologic findings may be focal or patchy. As a result, some patients require biopsy of both the right and the left lobes of the liver. A laparoscopic approach may be better suited for this purpose.",
"   </p>",
"   <p>",
"    A 2009 guideline from the American Association for the Study of Liver Diseases recommends performing a liver biopsy only when an obstructed hepatic venous outflow tract has not been demonstrated with noninvasive imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/20\">",
"     20",
"    </a>",
"    ]. We generally perform a liver biopsy when:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is confusion regarding the diagnosis (an uncommon situation given the multitude of available imaging tests).",
"     </li>",
"     <li>",
"      In patients with subacute presentations (ie, not obviously acute and fulminant or chronic with cirrhosis evident by clinical or radiologic features). Biopsies in such patients that show significant",
"      <span class=\"nowrap\">",
"       fibrosis/cirrhosis",
"      </span>",
"      may provide an impetus for transplant evaluation. In contrast, those showing only centrizonal congestion may indicate a patient who could benefit from shunt surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy for Budd-Chiari syndrome can be divided into medical treatment (including supportive care, anticoagulation, and thrombolysis), radiologic procedures (such as angioplasty, transjugular intrahepatic portosystemic shunt [TIPS] placement, and stenting) and surgical intervention (including shunting procedures and liver transplantation). The choice of a particular approach or combination of approaches depends upon the clinical and anatomic features of the Budd-Chiari syndrome that are specific to the individual patient, and the experience of the center. Sequential use of increasingly invasive procedures (based upon the clinical response) has been advocated in some centers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Optimal treatment of patients who are pregnant is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/23\">",
"     23",
"    </a>",
"    ]. The goals of therapy are to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prevent the propagation of the clot",
"     </li>",
"     <li>",
"      Restore patency of thrombosed veins",
"     </li>",
"     <li>",
"      Decompress the congested liver",
"     </li>",
"     <li>",
"      Address and prevent complications related to fluid retention, malnutrition, and portal hypertension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Individualized treatment can result in good clinical outcomes. In a series of 163 patients managed by contemporary approaches, one- and two-year survival rates were 87 and 82 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Budd-Chiari syndrome usually require symptomatic therapy for fluid retention, which usually includes diuretics and a low sodium diet. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=see_link\">",
"     \"Initial therapy of ascites in patients with cirrhosis\"",
"    </a>",
"    .) The American Association for the Study of Liver Diseases (AASLD) guideline for the management of adult patients with ascites due to cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/24\">",
"     24",
"    </a>",
"    ], as well as other AASLD guidelines, can be accessed through the AASLD web site at",
"    <a class=\"external\" href=\"file://www.aasld.org/practiceguidelines/Pages/default.aspx\">",
"     file://www.aasld.org/practiceguidelines/Pages/default.aspx",
"    </a>",
"    . Ascites and lower extremity edema can be difficult to control in some patients. Such patients may benefit from the use of support stockings or repeated large-volume paracenteses, but may require a shunting procedure to alleviate symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=see_link\">",
"     \"Treatment of diuretic-resistant ascites in patients with cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A careful dietary history should be obtained especially if there has been significant weight loss or other evidence of malnutrition. An attempt should be made to improve nutritional status.",
"   </p>",
"   <p>",
"    The underlying cause of the Budd-Chiari syndrome should be investigated, and appropriate therapy administered (",
"    <a class=\"graphic graphic_table graphicRef79884 \" href=\"UTD.htm?39/22/40299\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=see_link\">",
"     \"Etiology of the Budd-Chiari syndrome\"",
"    </a>",
"    .) The benefit of medical therapy for the underlying condition was illustrated in one series of 10 patients, 70 percent of whom were alive after a median follow-up of 40 months [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/25\">",
"     25",
"    </a>",
"    ]. Most patients have an underlying hypercoagulable disorder and will require chronic anticoagulation. Exceptions include patients who develop Budd-Chiari syndrome as a result of a web in the inferior vena cava or other anatomic abnormality that can be corrected surgically or radiologically [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/26\">",
"     26",
"    </a>",
"    ]. Patients with an underlying myeloproliferative disorder may benefit from treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    rather than anticoagulants such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation alone is unlikely to lead to sufficient recanalization of occluded vessels, or development of adequate collateral circulation to avoid the progression of liver disease. However, there are reports of good long-term survival with only medical therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the largest series (described above) included 237 patients treated at four centers between 1984 and 2001 of whom 72 percent received anticoagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/6\">",
"       6",
"      </a>",
"      ]. The authors generated a statistical model predicting categories of disease severity (Class I to III), which correlated with survival (",
"      <a class=\"graphic graphic_figure graphicRef57612 \" href=\"UTD.htm?7/29/7646\">",
"       figure 1",
"      </a>",
"      ). Independent variables predicting a worse prognosis included the presence of encephalopathy, ascites, an International Normalized Ratio of &gt;2.3, and higher bilirubin concentrations (variables that are notably similar to the Child-Pugh classification except for the absence of albumin). A trend for a benefit of anticoagulation on survival (RR 0.14, 95% CI 0.02 to 1.21) could only be demonstrated in patients with class I disease (ie, less severe disease).",
"     </li>",
"     <li>",
"      Another retrospective study examined factors associated with prognosis in a series of 120 patients with Budd-Chiari, 82 of whom had been treated with surgical portosystemic shunts, and 38 of whom had received only medical therapy (with diuretics and anticoagulants) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/29\">",
"       29",
"      </a>",
"      ]. Independent predictors identified on multivariate analysis associated with a worse prognosis included: older age at diagnosis, more severe liver failure, and the presence of refractory ascites. Patients with a favorable profile had up to an 80 percent five-year survival with medical therapy alone. However, only 13 patients fell into this category.",
"     </li>",
"     <li>",
"      A subsequent report from the same authors found that (in addition to the predictors described above) prognosis was worse in patients who presented with clinical features suggesting chronic disease [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/30\">",
"       30",
"      </a>",
"      ]. Surgical portosystemic shunting had no apparent benefit on survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of anticoagulation and diuretics alone as therapy for the Budd-Chiari syndrome should be reserved for two very small groups of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those who have chronic or subacute Budd-Chiari syndrome with well compensated liver disease at the time of presentation. However, additional measures to decompress the liver should be considered in such patients (particularly if they are not candidates for liver transplantation) in an attempt to delay progression of the liver disease.",
"     </li>",
"     <li>",
"      Those in whom other types of therapy are not feasible.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of anticoagulation should also be considered, especially in patients who present with bleeding complications. Patients receiving only medical therapy should be monitored closely for disease progression (ie, deterioration of hepatic synthetic function). In addition to standard laboratory studies, a reasonable approach is to perform serial upper endoscopies (looking for varices) and liver biopsies annually, tapering to every two to three years depending upon the overall health status of the patient. Bleeding complications appear to be common in patients maintained on anticoagulation, emphasizing the need for close follow-up and monitoring of coagulation status, especially during invasive procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Thrombolytic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic and locally administered thrombolytic agents have been used in the treatment of Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Although no study has directly compared the efficacy of local to systemic infusion, the ability to direct infusion to an affected vein could theoretically lead to a higher concentration and greater efficacy. The amount of medication administered during local infusion causes a comparable coagulopathy to systemic administration; thus, the bleeding risk is similar.",
"   </p>",
"   <p>",
"    Thrombolytic agents should",
"    <strong>",
"     not",
"    </strong>",
"    be used in the treatment of the chronic form of Budd-Chiari syndrome. Clots in such patients have matured and are unlikely to be recanalized by thrombolytic agents. Furthermore, because such patients may have developed portal hypertension, treatment can be associated with disastrous bleeding complications.",
"   </p>",
"   <p>",
"    Thrombolytic treatment can be considered in patients with the acute or subacute form of Budd-Chiari syndrome, in which blood clots are younger than three to four weeks. Published experience with thrombolytic agents in this setting is limited to small case series and individual reports, which have documented successful treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/32,35\">",
"     32,35",
"    </a>",
"    ]. However, enthusiasm for thrombolytic therapy in centers caring for a relatively large number of patients with Budd-Chiari syndrome is less than the published reports indicate. In most cases, treatment has limited efficacy, and exposes the patient to the risks of thrombolytic therapy, which include bleeding, stroke, and pulmonary embolism.",
"   </p>",
"   <p>",
"    We use thrombolytic therapy only in patients in whom the clot is well defined on venography and known to be recent, and in whom there are no contraindications to the use of thrombolytic agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=see_link\">",
"     \"Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy\"",
"    </a>",
"    .) We avoid using thrombolytic agents in patients who have extensive clot involving the intrahepatic vena cava and hepatic veins or a clot of unknown age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Radiologic treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to access the hepatic venous system intravascularly has permitted the application of minimally invasive procedures to restore hepatic venous drainage. These include angioplasty alone or with placement of a stent and TIPS. These interventional procedures are assuming a major role in the management of patients with recent onset Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. One group, for example, described five-year transplant-free survival rates of 77 to 100 percent using an approach involving transvenous and percutaneous-transvenous approaches or TIPS (when recanalization was not possible) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Angioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomy of the hepatic venous circulation in some patients with Budd-Chiari syndrome may reveal a focal abnormality that is amenable to balloon angioplasty. A membranous web in the inferior vena cava, for example, can be dilated [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/26,38\">",
"     26,38",
"    </a>",
"    ]. Balloon dilation of hepatic veins may also be effective in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/39\">",
"     39",
"    </a>",
"    ]. Angioplasty can be combined with thrombolytic therapy in patients in whom there is thrombosis of a single hepatic vein [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major problem with angioplasty for Budd-Chiari syndrome is that reocclusion of the affected vessel is common. Placement of an expandable metal stent in the occluded vessel following angioplasty may help to maintain patency [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/41-45\">",
"     41-45",
"    </a>",
"    ]. Experience with this technique is limited to small numbers of patients; long-term survival with improvement in liver function and lessening of portal hypertension has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/42\">",
"     42",
"    </a>",
"    ]. However, many patients eventually require liver transplantation.",
"   </p>",
"   <p>",
"    Once inserted, the stent cannot be removed. Therefore, placement should be coordinated with a liver transplant team in patients who would otherwise be eligible for liver transplantation. Placement of a stent above the intrahepatic inferior vena cava, for example, complicates, and in some cases precludes, anastomosis of the donor and host inferior vena cava required during liver transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Transjugular intrahepatic portosystemic shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rational for the use of a TIPS in the Budd-Chiari syndrome is to decompress congested segments in the liver by creation of an alternative venous outflow tract.",
"   </p>",
"   <p>",
"    Several reports suggest that TIPS can be successfully performed in patients with Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/41,46-53\">",
"     41,46-53",
"    </a>",
"    ]. In one of the largest series (which included patients with severe Budd-Chiari syndrome who did not respond to medical therapy or attempts at achieving recanalization), overall five-year survival after TIPS (84 percent) was similar to five-year survival from published reports of orthotopic liver transplantation for Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/52\">",
"     52",
"    </a>",
"    ]. Transplant-free survival at one and five years after TIPS was 88 and 78 percent, respectively. A prognostic score based upon age, bilirubin and INR levels predicted a small group of patients expected to have high mortality after TIPS, who would be better managed by liver transplantation.",
"   </p>",
"   <p>",
"    However, TIPS may not be technically feasible in many patients, may only drain a small portion of the liver, and is associated with a high rate of occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/54\">",
"     54",
"    </a>",
"    ]. In addition, many patients in whom TIPS is considered may be candidates for angioplasty with placement of a stent, thereby restoring flow through the native outflow tract. The availability of polytetrafluoroethylene-covered stents, which have a reduced incidence of TIPS dysfunction, may enhance enthusiasm for their use [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15448?source=see_link\">",
"     \"Complications of transjugular intrahepatic portosystemic shunts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result of these considerations, we reserve the use of TIPS for patients who do not respond to dilation of a hepatic venous outflow stricture or in whom a dilatable lesion cannot be found. TIPS may also have a role as a temporizing measure prior to liver transplantation in patients with acute, fulminant Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/56\">",
"     56",
"    </a>",
"    ]. Placement of TIPS in these patients, if not performed properly, can result in complication such as portal vein thrombosis, which may greatly complicate or preclude subsequent liver transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principle of surgical therapy for Budd-Chiari syndrome is to restore hepatic venous drainage and thereby decompress the liver. Most surgical shunts drain the portal or mesenteric venous system into the inferior vena cava or another systemic vein. This allows blood entering the liver via the hepatic artery to have a low pressure route by which to drain out of the liver. Severe acute hepatocellular necrosis caused by pressure-induced atrophy of hepatocytes will often regress following the creation of decompressive shunts.",
"   </p>",
"   <p>",
"    Surgical thrombectomy alone is usually is not technically possible. It has been performed in association with dorsocranial liver resection with good results in selected cases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/57,58\">",
"     57,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Surgical decompression is unlikely to be beneficial in patients who have cirrhosis or biochemical evidence of advanced liver dysfunction (elevated prothrombin time and serum bilirubin level, decreased serum albumin). Such patients are best managed with liver transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Surgical approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple surgical approaches have been attempted in the treatment of Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/59-64\">",
"     59-64",
"    </a>",
"    ]. Because of the availability of TIPS for the treatment of refractory portal hypertensive bleeding and the rarity of Budd-Chiari syndrome, relatively few vascular surgeons routinely perform shunt surgery. Referral may be indicated if an experienced surgeon is unavailable.",
"   </p>",
"   <p>",
"    As in the case of self-expanding metal stents, the decision to perform shunt surgery should be coordinated with a liver transplant team, since shunt surgery may not preclude the need for subsequent liver transplantation. The underlying cause of the thrombotic diathesis should be identified and treated prior to considering shunt surgery.",
"   </p>",
"   <p>",
"    Side-to-side portacaval, splenorenal, and mesocaval shunts all are feasible only if the inferior vena cava is patent and without a significant pressure gradient between its infrahepatic and suprahepatic portions. It has been suggested that the infrahepatic pressure in the inferior vena cava should be at least 10 mmHg lower than the portal pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/65\">",
"     65",
"    </a>",
"    ]. A simple and direct side-to-side portacaval anastomosis may also be technically difficult in the presence of caudate lobe hypertrophy. Such patients often require a mesocaval shunt.",
"   </p>",
"   <p>",
"    Synthetic shunts can be constructed from the portal-mesenteric system to the right atrium (meso-atrial shunt), which can bypass the inferior vena cava if it is occluded or there is a significant pressure gradient. However, shunts that require artificial graft material are more likely to be complicated by thrombosis. To overcome this complication, one group described long-term patency of a shunt involving a side-to-side portacaval shunt combined with a cavoatrial shunt through a Gore-Tex graft [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Five-year survival following shunt surgery depends upon the extent of liver damage prior to surgery, and the continued patency of the shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/64,66\">",
"     64,66",
"    </a>",
"    ]. Five-year survival as high as 90 percent has been reported in patients who underwent shunt surgery prior to the development of cirrhosis, and whose shunts remained patent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/6,64,66,67\">",
"     6,64,66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Perioperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perioperative management of patients undergoing surgical decompression is critical for determining their outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/68\">",
"     68",
"    </a>",
"    ]. Maintenance of shunt patency often requires anticoagulation. In addition, Doppler ultrasound should be performed periodically to evaluate shunt patency, particularly for shunts in which a synthetic graft has been used.",
"   </p>",
"   <p>",
"    Clinical or biochemical deterioration in patients following shunt surgery should be investigated by angiography to determine whether the shunt has thrombosed, which may be corrected by angioplasty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation (OLT) may be the only option for patients with Budd-Chiari syndrome who are not candidates for radiologic or surgical decompression or who have decompensated cirrhosis. Patients who developed the Budd-Chiari syndrome as a result of protein S, protein C, or antithrombin III deficiency may also be cured of their clotting tendency by liver transplantation, since the transplanted liver produces normal amounts of these enzymes.",
"   </p>",
"   <p>",
"    Survival following OLT depends upon the underlying cause of the Budd-Chiari syndrome and the patient's condition at the time of the transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. Survival may have improved in recent years with advances in liver transplantation technology and routine use of the MELD score [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the largest series (510 patients) compared survival in patients who underwent transplantation after introduction of the MELD score to the pre-MELD era [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/71\">",
"       71",
"      </a>",
"      ]. Three-year graft survival (81 versus 65 percent) and patient survival (85 versus 73 percent) were significantly better following introduction of the MELD score.",
"     </li>",
"     <li>",
"      In another large series (248 patients), overall survival was 76, 71, and 68 percent at one, five, and ten years respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/70\">",
"       70",
"      </a>",
"      ]. Most deaths (77 percent) occurred in the first three months. The only predictor of mortality was impaired renal function and a history of a shunt.",
"     </li>",
"     <li>",
"      Ten-year survival ranged from 69 to 84 percent in two other series [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/68,72\">",
"       68,72",
"      </a>",
"      ]. In one report, vascular complications were more common in patients transplanted for Budd-Chiari syndrome than other indications [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/72\">",
"       72",
"      </a>",
"      ]. Although survival was similar to or better than that of patients transplanted for other indications, these patients may have had less severe liver dysfunction prior to transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy in women with Budd-Chiari syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14726?source=see_link\">",
"     \"Intercurrent hepatobiliary disease during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     AASLD GUIDELINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2009 guideline from the American Association for the Study of Liver Diseases includes the following recommendations regarding treatment of Budd-Chiari syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Correct without delay the underlying risk factor(s) for venous thrombosis.",
"     </li>",
"     <li>",
"      Initiate anticoagulation therapy immediately. Use low molecular weight",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , targeting anti-Xa activity to 0.5-0.8 int.",
"      <span class=\"nowrap\">",
"       unit/mL.",
"      </span>",
"      Change to an oral anticoagulation agent when clinically appropriate, targeting the INR between 2 and 3.",
"     </li>",
"     <li>",
"      Maintain permanent anticoagulation therapy unless a major contraindication is present or complication occurs.",
"     </li>",
"     <li>",
"      Treat complications of portal hypertension as recommended for other types of liver disease.",
"     </li>",
"     <li>",
"      Check for a venous obstruction amenable to percutaneous",
"      <span class=\"nowrap\">",
"       angioplasty/stenting",
"      </span>",
"      in all symptomatic patients and treat accordingly.",
"     </li>",
"     <li>",
"      In patients without ongoing improvement on anticoagulation therapy (with or without angioplasty), consider transjugular intrahepatic portosystemic shunt (TIPS).",
"     </li>",
"     <li>",
"      Consider liver transplantation if TIPS insertion fails or does not improve the patient's condition and in those with fulminant hepatic failure.",
"     </li>",
"     <li>",
"      Coordinate care with a transplant center.",
"     </li>",
"     <li>",
"      Monitor patients with longstanding, well controlled Budd-Chiari syndrome for the late development of hepatocellular cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?3/22/3434/abstract/73\">",
"       73",
"      </a>",
"      ] and transformation of underlying myeloproliferative disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Budd-Chiari syndrome can be defined as any pathophysiologic process that results in interruption or diminution of the normal blood flow out of the liver. As commonly used, however, the Budd-Chiari syndrome implies thrombosis of the hepatic veins",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the intrahepatic or suprahepatic inferior vena cava. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Budd-Chiari syndrome is more common in women, and usually presents in the third or fourth decade, although it may occur in children or the elderly. Although there is variability in how patients present, presentation can generally be categorized as acute (and perhaps fulminant), subacute, or chronic. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with acute disease usually present with severe right upper quadrant pain and hepatomegaly. Jaundice and ascites may not be apparent initially, but often develop rapidly. Ascites is detectable by ultrasound in more than 90 percent of patients. Variceal bleeding may also occur. The acute form of Budd-Chiari syndrome may share features with other causes of acute failure, including ischemic, viral,",
"      <span class=\"nowrap\">",
"       malignant/infiltrative,",
"      </span>",
"      and toxic hepatitis, although serum aminotransferases are usually not as elevated. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=see_link\">",
"       \"Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The subacute and chronic forms of Budd-Chiari syndrome have been present for several weeks to more than six months prior to clinical presentation. The clinical manifestations and duration of disease prior to presentation depend upon the particular vessels that are occluded, the extent of occlusion, and the recruitment of collateral circulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic or subacute Budd-Chiari syndrome should be considered in the differential diagnosis of otherwise unexplained liver dysfunction, particularly in patients in whom ascites is a principal feature, or in those with a known risk factor for Budd-Chiari syndrome (",
"      <a class=\"graphic graphic_table graphicRef79884 \" href=\"UTD.htm?39/22/40299\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=see_link\">",
"       \"Etiology of the Budd-Chiari syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis can be established noninvasively by ultrasonography with Doppler studies, CT scan, or magnetic resonance angiography (MRI angiography). The gold standard for diagnosis is venography, which is performed by accessing the hepatic venous circulation percutaneously. Venography should be performed if noninvasive tests are negative or nondiagnostic but there is strong clinical suspicion for the disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The choice of noninvasive diagnostic tests depends upon the suspicion for the disease, and the available expertise. We usually begin with Doppler ultrasonography. In patients with an unremarkable ultrasound examination but in whom the suspicion for Budd-Chiari is high, magnetic resonance imaging is a reasonable next option. Venography can be used to confirm the diagnosis and to plan therapeutic interventions.",
"     </li>",
"     <li>",
"      Therapy for Budd-Chiari syndrome can be divided into medical treatment (including supportive care, anticoagulation, and thrombolysis), radiologic procedures (such as angioplasty, transjugular intrahepatic portosystemic shunt placement, and stenting) and surgical intervention (including shunt procedures and liver transplantation). The choice of a particular approach or combination of approaches depends upon the clinical and anatomic features of the Budd-Chiari syndrome that are specific to the individual patient, and the experience of the center.",
"      <br/>",
"      <br/>",
"      The goals of therapy are to:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Prevent the propagation of the clot",
"     </li>",
"     <li>",
"      Decompress the congested liver",
"     </li>",
"     <li>",
"      Address and prevent complications related to fluid retention, malnutrition, and portal hypertension",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/1\">",
"      Menon KV, Shah V, Kamath PS. The Budd-Chiari syndrome. N Engl J Med 2004; 350:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/2\">",
"      Okuda K, Kage M, Shrestha SM. Proposal of a new nomenclature for Budd-Chiari syndrome: hepatic vein thrombosis versus thrombosis of the inferior vena cava at its hepatic portion. Hepatology 1998; 28:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/3\">",
"      Valla DC. The diagnosis and management of the Budd-Chiari syndrome: consensus and controversies. Hepatology 2003; 38:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/4\">",
"      Klein AS, Molmenti EP. Surgical treatment of Budd-Chiari syndrome. Liver Transpl 2003; 9:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/5\">",
"      Mahmoud AE, Mendoza A, Meshikhes AN, et al. Clinical spectrum, investigations and treatment of Budd-Chiari syndrome. QJM 1996; 89:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/6\">",
"      Darwish Murad S, Valla DC, de Groen PC, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. Hepatology 2004; 39:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/7\">",
"      Darwish Murad S, Plessier A, Hernandez-Guerra M, et al. Etiology, management, and outcome of the Budd-Chiari syndrome. Ann Intern Med 2009; 151:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/8\">",
"      Fickert P, Ramschak H, Kenner L, et al. Acute Budd-Chiari syndrome with fulminant hepatic failure in a pregnant woman with factor V Leiden mutation. Gastroenterology 1996; 111:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/9\">",
"      Rautou PE, Moucari R, Cazals-Hatem D, et al. Levels and initial course of serum alanine aminotransferase can predict outcome of patients with Budd-Chiari syndrome. Clin Gastroenterol Hepatol 2009; 7:1230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/10\">",
"      Hadengue A, Poliquin M, Vilgrain V, et al. The changing scene of hepatic vein thrombosis: recognition of asymptomatic cases. Gastroenterology 1994; 106:1042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/11\">",
"      De BK, Sen S, Biswas PK, et al. Occurrence of hepatopulmonary syndrome in Budd-Chiari syndrome and the role of venous decompression. Gastroenterology 2002; 122:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/12\">",
"      Mahmoud AE, Helmy AS, Billingham L, Elias E. Poor prognosis and limited therapeutic options in patients with Budd-Chiari syndrome and portal venous system thrombosis. Eur J Gastroenterol Hepatol 1997; 9:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/13\">",
"      Mitchell MC, Boitnott JK, Kaufman S, et al. Budd-Chiari syndrome: etiology, diagnosis and management. Medicine (Baltimore) 1982; 61:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/14\">",
"      Gupta S, Barter S, Phillips GW, et al. Comparison of ultrasonography, computed tomography and 99mTc liver scan in diagnosis of Budd-Chiari syndrome. Gut 1987; 28:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/15\">",
"      Soyer P, Rabenandrasana A, Barge J, et al. MRI of Budd-Chiari syndrome. Abdom Imaging 1994; 19:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/16\">",
"      Friedman AC, Ramchandani P, Black M, et al. Magnetic resonance imaging diagnosis of Budd-Chiari syndrome. Gastroenterology 1986; 91:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/17\">",
"      Lin J, Zhou KR, Chen ZW, et al. Vena cava 3D contrast-enhanced MR venography: a pictorial review. Cardiovasc Intervent Radiol 2005; 28:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/18\">",
"      Cazals-Hatem D, Vilgrain V, Genin P, et al. Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: a study in 17 explanted livers. Hepatology 2003; 37:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/19\">",
"      Tang TJ, Batts KP, de Groen PC, et al. The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome. J Hepatol 2001; 35:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/20\">",
"      DeLeve LD, Valla DC, Garcia-Tsao G, American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009; 49:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/21\">",
"      Plessier A, Sibert A, Consigny Y, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. Hepatology 2006; 44:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/22\">",
"      Klein AS. Management of Budd-Chiari syndrome. Liver Transpl 2006; 12:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/23\">",
"      Grant WJ, McCashland T, Botha JF, et al. Acute Budd-Chiari syndrome during pregnancy: surgical treatment and orthotopic liver transplantation with successful completion of the pregnancy. Liver Transpl 2003; 9:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/24\">",
"      Runyon BA, Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Management of adult patients with ascites due to cirrhosis. Hepatology 2004; 39:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/25\">",
"      Min AD, Atillasoy EO, Schwartz ME, et al. Reassessing the role of medical therapy in the management of hepatic vein thrombosis. Liver Transpl Surg 1997; 3:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/26\">",
"      Yang XL, Cheng TO, Chen CR. Successful treatment by percutaneous balloon angioplasty of Budd-Chiari syndrome caused by membranous obstruction of inferior vena cava: 8-year follow-up study. J Am Coll Cardiol 1996; 28:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/27\">",
"      Melear JM, Goldstein RM, Levy MF, et al. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation 2002; 74:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/28\">",
"      Martinelli I, Franchini M, Mannucci PM. How I treat rare venous thromboses. Blood 2008; 112:4818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/29\">",
"      Zeitoun G, Escolano S, Hadengue A, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology 1999; 30:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/30\">",
"      Langlet P, Escolano S, Valla D, et al. Clinicopathological forms and prognostic index in Budd-Chiari syndrome. J Hepatol 2003; 39:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/31\">",
"      Rautou PE, Douarin L, Denninger MH, et al. Bleeding in patients with Budd-Chiari syndrome. J Hepatol 2011; 54:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/32\">",
"      Raju GS, Felver M, Olin JW, Satti SD. Thrombolysis for acute Budd-Chiari syndrome: case report and literature review. Am J Gastroenterol 1996; 91:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/33\">",
"      Greenwood LH, Yrizarry JM, Hallett JW Jr, Scoville GS Jr. Urokinase treatment of Budd-Chiari syndrome. AJR Am J Roentgenol 1983; 141:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/34\">",
"      Sholar PW, Bell WR. Thrombolytic therapy for inferior vena cava thrombosis in paroxysmal nocturnal hemoglobinuria. Ann Intern Med 1985; 103:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/35\">",
"      Sharma S, Texeira A, Texeira P, et al. Pharmacological thrombolysis in Budd Chiari syndrome: a single centre experience and review of the literature. J Hepatol 2004; 40:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/36\">",
"      Wang ZG, Zhang FJ, Yi MQ, Qiang LX. Evolution of management for Budd-Chiari syndrome: a team's view from 2564 patients. ANZ J Surg 2005; 75:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/37\">",
"      Eapen CE, Velissaris D, Heydtmann M, et al. Favourable medium term outcome following hepatic vein recanalisation and/or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome. Gut 2006; 55:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/38\">",
"      Sparano J, Chang J, Trasi S, Bonanno C. Treatment of the Budd-Chiari syndrome with percutaneous transluminal angioplasty. Case report and review of the literature. Am J Med 1987; 82:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/39\">",
"      Uflacker R, Francisconi CF, Rodriguez MP, Amaral NM. Percutaneous transluminal angioplasty of the hepatic veins for treatment of Budd-Chiari syndrome. Radiology 1984; 153:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/40\">",
"      Fisher NC, McCafferty I, Dolapci M, et al. Managing Budd-Chiari syndrome: a retrospective review of percutaneous hepatic vein angioplasty and surgical shunting. Gut 1999; 44:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/41\">",
"      Lopez RR Jr, Benner KG, Hall L, et al. Expandable venous stents for treatment of the Budd-Chiari syndrome. Gastroenterology 1991; 100:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/42\">",
"      Witte AM, Kool LJ, Veenendaal R, et al. Hepatic vein stenting for Budd-Chiari syndrome. Am J Gastroenterol 1997; 92:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/43\">",
"      Gillams A, Dick R, Platts A, et al. Dilatation of the inferior vena cava using an expandable metal stent in Budd-Chiari syndrome. J Hepatol 1991; 13:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/44\">",
"      Xue H, Li YC, Shakya P, et al. The role of intravascular intervention in the management of Budd-Chiari syndrome. Dig Dis Sci 2010; 55:2659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/45\">",
"      Han G, Qi X, Zhang W, et al. Percutaneous recanalization for Budd-Chiari syndrome: an 11-year retrospective study on patency and survival in 177 Chinese patients from a single center. Radiology 2013; 266:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/46\">",
"      Ochs A, Sellinger M, Haag K, et al. Transjugular intrahepatic portosystemic stent-shunt (TIPS) in the treatment of Budd-Chiari syndrome. J Hepatol 1993; 18:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/47\">",
"      Peltzer MY, Ring EJ, LaBerge JM, et al. Treatment of Budd-Chiari syndrome with a transjugular intrahepatic portosystemic shunt. J Vasc Interv Radiol 1993; 4:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/48\">",
"      Blum U, R&ouml;ssle M, Haag K, et al. Budd-Chiari syndrome: technical, hemodynamic, and clinical results of treatment with transjugular intrahepatic portosystemic shunt. Radiology 1995; 197:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/49\">",
"      Ganger DR, Klapman JB, McDonald V, et al. Transjugular intrahepatic portosystemic shunt (TIPS) for Budd-Chiari syndrome or portal vein thrombosis: review of indications and problems. Am J Gastroenterol 1999; 94:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/50\">",
"      Perell&oacute; A, Garc&iacute;a-Pag&aacute;n JC, Gilabert R, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology 2002; 35:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/51\">",
"      Mancuso A, Fung K, Mela M, et al. TIPS for acute and chronic Budd-Chiari syndrome: a single-centre experience. J Hepatol 2003; 38:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/52\">",
"      Garcia-Pag&aacute;n JC, Heydtmann M, Raffa S, et al. TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. Gastroenterology 2008; 135:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/53\">",
"      Angermayr B, Cejna M, Schmid M, et al. Pregnancy after placement of a tranjugular intrahepatic portosystmic shunt (TIPS) in two patients with Budd-Chiari syndrome (abstract). Gastroenterology 2004; 126(Suppl):A731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/54\">",
"      Bachet JB, Condat B, Hag&egrave;ge H, et al. Long-term portosystemic shunt patency as a determinant of outcome in Budd-Chiari syndrome. J Hepatol 2007; 46:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/55\">",
"      Hern&aacute;ndez-Guerra M, Turnes J, Rubinstein P, et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. Hepatology 2004; 40:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/56\">",
"      Shrestha R, Durham JD, Wachs M, et al. Use of transjugular intrahepatic portosystemic shunt as a bridge to transplantation in fulminant hepatic failure due to Budd-Chiari syndrome. Am J Gastroenterol 1997; 92:2304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/57\">",
"      Bansky G, Ernest C, Jenni R, et al. Treatment of Budd-Chiari syndrome by dorsocranial liver resection and direct hepatoatrial anastomosis. J Hepatol 1986; 2:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/58\">",
"      Vogt PR, Andersson LC, Jenni R, et al. Dorsocranial liver resection and direct hepatoatrial anastomosis for hepatic venous outflow obstruction: long-term outcome and functional results. Am J Gastroenterol 1996; 91:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/59\">",
"      Orloff MJ, Johansen KH. Treatment of Budd-Chiari syndrome by side-to-side portacaval shunt: experimental and clinical results. Ann Surg 1978; 188:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/60\">",
"      Cameron JL, Herlong HF, Sanfey H, et al. The Budd-Chiari syndrome. Treatment by mesenteric-systemic venous shunts. Ann Surg 1983; 198:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/61\">",
"      Imaoka S, Okamoto N, Kobayashi T, et al. Treatment of inferior vena cava obstruction producing Budd-Chiari syndrome. Arch Surg 1984; 119:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/62\">",
"      McDermott WV, Stone MD, Bothe A Jr, Trey C. Budd-Chiari syndrome. Historical and clinical review with an analysis of surgical corrective procedures. Am J Surg 1984; 147:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/63\">",
"      Orloff MJ, Girard B. Long term results of treatment of Budd-Chiari syndrome by side to side portacaval shunt. Surg Gynecol Obstet 1989; 168:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/64\">",
"      Orloff MJ, Daily PO, Orloff SL, et al. A 27-year experience with surgical treatment of Budd-Chiari syndrome. Ann Surg 2000; 232:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/65\">",
"      Shill M, Henderson JM, Tavill AS. The Budd-Chiari syndrome revisited. Gastroenterologist 1994; 2:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/66\">",
"      Panis Y, Belghiti J, Valla D, et al. Portosystemic shunt in Budd-Chiari syndrome: long-term survival and factors affecting shunt patency in 25 patients in Western countries. Surgery 1994; 115:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/67\">",
"      Orloff MJ, Orloff MS, Daily PO. Long-term results of treatment of Budd-Chiari syndrome with portal decompression. Arch Surg 1992; 127:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/68\">",
"      Ringe B, Lang H, Oldhafer KJ, et al. Which is the best surgery for Budd-Chiari syndrome: venous decompression or liver transplantation? A single-center experience with 50 patients. Hepatology 1995; 21:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/69\">",
"      Campbell DA Jr, Rolles K, Jamieson N, et al. Hepatic transplantation with perioperative and long term anticoagulation as treatment for Budd-Chiari syndrome. Surg Gynecol Obstet 1988; 166:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/70\">",
"      Mentha G, Giostra E, Majno PE, et al. Liver transplantation for Budd-Chiari syndrome: A European study on 248 patients from 51 centres. J Hepatol 2006; 44:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/71\">",
"      Segev DL, Nguyen GC, Locke JE, et al. Twenty years of liver transplantation for Budd-Chiari syndrome: a national registry analysis. Liver Transpl 2007; 13:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/72\">",
"      Ulrich F, Pratschke J, Neumann U, et al. Eighteen years of liver transplantation experience in patients with advanced Budd-Chiari syndrome. Liver Transpl 2008; 14:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/22/3434/abstract/73\">",
"      Moucari R, Rautou PE, Cazals-Hatem D, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors. Gut 2008; 57:828.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3562 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-FA0D210239-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_22_3434=[""].join("\n");
var outline_f3_22_3434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H31\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Subacute and chronic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Doppler ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sulfur-colloid scintigraphy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Venography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Arteriography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Liver biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Recommendation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Thrombolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Radiologic treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Angioplasty",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Stenting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Transjugular intrahepatic portosystemic shunt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Surgical approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Perioperative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      AASLD GUIDELINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3562\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3562|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/63/43006\" title=\"diagnostic image 1\">",
"      Budd Chiari venacavagram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?5/47/5874\" title=\"diagnostic image 2\">",
"      Budd Chiari CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3562|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/29/7646\" title=\"figure 1\">",
"      Survival Budd Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3562|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/22/40299\" title=\"table 1\">",
"      Causes of Budd Chiari syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/17/2330?source=related_link\">",
"      Acute liver failure in adults: Etiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15448?source=related_link\">",
"      Complications of transjugular intrahepatic portosystemic shunts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23194?source=related_link\">",
"      Diagnostic approach to the patient with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/53/31575?source=related_link\">",
"      Etiology of the Budd-Chiari syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/43/14010?source=related_link\">",
"      Evaluation of adults with ascites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/43/1721?source=related_link\">",
"      Fibrinolytic therapy in acute ST elevation myocardial infarction: Initiation of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3640?source=related_link\">",
"      Hepatopulmonary syndrome: Prevalence, causes, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19145?source=related_link\">",
"      Initial therapy of ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14726?source=related_link\">",
"      Intercurrent hepatobiliary disease during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28054?source=related_link\">",
"      Magnetic resonance imaging of the hepatobiliary tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40009?source=related_link\">",
"      Pathogenesis and clinical features of hepatic sinusoidal obstruction syndrome (veno-occlusive disease) following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/40/35465?source=related_link\">",
"      Treatment of diuretic-resistant ascites in patients with cirrhosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_22_3435="Risk factors for bleomycin toxicity";
var content_f3_22_3435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75966&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for bleomycin pulmonary toxicity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Probable risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total cumulative dose &ge;400 units",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exposure to high partial pressure of oxygen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age over 40",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cigarette smoking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Possible risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Concurrent use of cisplatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Concurrent use of granulocyte colony stimulating factor",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_22_3435=[""].join("\n");
var outline_f3_22_3435=null;
var title_f3_22_3436="Differential diagnosis of upper abdominal pain";
var content_f3_22_3436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F65698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F65698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of upper abdominal pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Diagnosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Functional dyspepsia (up to 60 percent)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Dyspepsia caused by structural or biochemical disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Peptic ulcer disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gastroesophageal reflux disease (GERD)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Biliary pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Chronic abdominal wall pain",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gastric or esophageal cancer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Gastroparesis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Pancreatitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Carbohydrate malabsorption",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Medications (including potassium supplements, digitalis, iron, theophylline, oral antibiotics [especially ampillin and erythromycin], NSAIDs, corticosteroids, niacin, gemfibrozil, narcotics, colchicine, quinidine, estrogens, levodopa)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Infiltrative diseases of the stomach (eg, Crohn's disease sarcoidosis)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Metabolic disturbances (hypercalcemia, hyperkalemia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hepatoma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ischemic bowel disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Systemic disorders (diabetes mellitus, thyroid and parathyroid disorders, connective tissue disease)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Intestinal parasites (Giardia, Strongyloides)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Abdominal cancer, especially pancreatic cancer",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <ol>",
"      <li>",
"       Talley NJ, Silverstein MD, Agreus L, et al. Gastroenterology 1998; 114:582.",
"      </li>",
"      <li>",
"       Fisher RS, Parkman HP. N Engl J Med 1998; 339:1376.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_22_3436=[""].join("\n");
var outline_f3_22_3436=null;
var title_f3_22_3437="Options for diabetes Tx";
var content_f3_22_3437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56876&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of glucose-lowering interventions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Intervention",
"       </td>",
"       <td class=\"subtitle1\">",
"        Expected decrease in A1C with monotherapy, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Tier 1: well-validated core",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Step 1: initial therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lifestyle to decrease weight and increase activity",
"       </td>",
"       <td>",
"        1.0 to 2.0",
"       </td>",
"       <td>",
"        Broad benefits",
"       </td>",
"       <td>",
"        Insufficient for most within first year",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Metformin",
"       </td>",
"       <td>",
"        1.0 to 2.0",
"       </td>",
"       <td>",
"        Weight neutral",
"       </td>",
"       <td>",
"        GI side effects, contraindicated with renal insufficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"4\">",
"        Step 2: additional therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Insulin",
"       </td>",
"       <td>",
"        1.5 to 3.5",
"       </td>",
"       <td>",
"        No dose limit, rapidly effective, improved lipid profile",
"       </td>",
"       <td>",
"        One to four injections daily, monitoring, weight gain, hypoglycemia, analogues are expensive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Sulfonylurea",
"       </td>",
"       <td>",
"        1.0 to 2.0",
"       </td>",
"       <td>",
"        Rapidly effective",
"       </td>",
"       <td>",
"        Weight gain, hypoglycemia (especially with glibenclamide or chlorpropamide)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Tier 2: less well validated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        TZDs",
"       </td>",
"       <td>",
"        0.5 to 1.4",
"       </td>",
"       <td>",
"        Improved lipid profile (pioglitazone), potential decrease in MI (pioglitazone)",
"       </td>",
"       <td>",
"        Fluid retention, HF, weight gain, bone fractures, expensive, potential increase in MI (rosiglitazone)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        GLP-1 agonist",
"       </td>",
"       <td>",
"        0.5 to 1.0",
"       </td>",
"       <td>",
"        Weight loss",
"       </td>",
"       <td>",
"        Requires injection, frequent GI side effects, long-term safety not established, expensive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Other therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &alpha;-Glucosidase inhibitor",
"       </td>",
"       <td>",
"        0.5 to 0.8",
"       </td>",
"       <td>",
"        Weight neutral",
"       </td>",
"       <td>",
"        Frequent GI side effects, three times/day dosing, expensive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glinide",
"       </td>",
"       <td>",
"        0.5 to 1.5*",
"       </td>",
"       <td>",
"        Rapidly effective",
"       </td>",
"       <td>",
"        Weight gain, three times/day dosing, hypoglycemia, expensive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pramlintide",
"       </td>",
"       <td>",
"        0.5 to 1.0",
"       </td>",
"       <td>",
"        Weight loss",
"       </td>",
"       <td>",
"        Three injections daily, frequent GI side effects, long-term safety not established, expensive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DPP-4 inhibitor",
"       </td>",
"       <td>",
"        0.5 to 0.8",
"       </td>",
"       <td>",
"        Weight neutral",
"       </td>",
"       <td>",
"        Long-term safety not established, expensive",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HF: heart failure; GI: gastrointestinal; MI: myocardial infarction.",
"     <br>",
"      * Repaglinide more effective in lowering A1C than nateglinide.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nathan DM, Buse JB, Davidson MB, et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32:193-203. Copyright &copy; 2009 American Diabetes.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_22_3437=[""].join("\n");
var outline_f3_22_3437=null;
var title_f3_22_3438="CDC guideline for emergency contraception";
var content_f3_22_3438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82516&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classifications for emergency contraceptive pills*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clarifications/evidence/comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Personal characteristics and reproductive history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pregnancy",
"       </td>",
"       <td>",
"        Not applicable",
"       </td>",
"       <td>",
"        <em>",
"         Clarification:",
"        </em>",
"        Although this method is not indicated for a woman with a known or suspected pregnancy, no harm to the woman, the course of her pregnancy, or the fetus if ECPs are inadvertently used is known to exist.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Breastfeeding",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Past ectopic pregnancy",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        History of bariatric surgery",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. Restrictive procedures: decrease storage capacity of the stomach (vertical banded gastroplasty, laparoscopic adjustable gastric band, laparoscopic sleeve gastrectomy)",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. Malabsorptive procedures: decrease absorption of nutrients and calories by shortening the functional length of the small intestine (Roux-en-Y gastric bypass, biliopancreatic diversion)",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        <em>",
"         Comment:",
"        </em>",
"        Bariatric surgical procedures involving a malabsorptive component have the potential to decrease oral contraceptive effectiveness, perhaps further decreased by postoperative complications such as long-term diarrhea and/or vomiting. Because of these malabsorptive concerns, an emergency IUD might be more appropriate than ECPs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Cardiovascular disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        History of severe cardiovascular complications",
"        <sup>",
"         &bull;",
"        </sup>",
"        (ischemic heart disease, cerebrovascular attack, or other thromboembolic conditions)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        <em>",
"         Comment:",
"        </em>",
"        The duration of ECP use is less than that of regular use of COCs or POPs and thus would be expected to have less clinical impact.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Angina pectoris",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        <em>",
"         Comment:",
"        </em>",
"        The duration of ECP use is less than that of regular use of COCs or POPs and thus would be expected to have less clinical impact.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Rheumatic diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Rheumatoid arthritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. On immunosuppressive therapy",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. Not on immunosuppressive therapy",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Neurologic conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Migraine",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        <em>",
"         Comment:",
"        </em>",
"        The duration of ECP use is less than that of regular use of COCs or POPs and thus would be expected to have less clinical impact.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Gastrointestinal conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Inflammatory bowel disease (ulcerative colitis, Crohn disease)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe liver disease",
"        <sup>",
"         &bull;",
"        </sup>",
"        (including jaundice)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        <em>",
"         Comment:",
"        </em>",
"        The duration of ECP use is less than that of regular use of COCs or POPs and thus would be expected to have less clinical impact.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Solid organ transplantation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Solid organ transplantation",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        a. Complicated: graft failure (acute or chronic), rejection, cardiac allograft vasculopathy",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        b. Uncomplicated",
"       </td>",
"       <td class=\"sublist_other\">",
"        1",
"       </td>",
"       <td class=\"sublist_other\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Repeated ECP use",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        <em>",
"         Clarification:",
"        </em>",
"        Recurrent ECP use is an indication that the woman requires further counseling about other contraceptive options. Frequently repeated ECP use may be harmful for women with conditions classified as 2, 3, or 4 for CHC or POC use.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rape",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        <em>",
"         Comment:",
"        </em>",
"        Use of ECPs in cases of rape has no restrictions.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    1 = A condition for which there is no restriction for the use of the contraceptive method.",
"    <br>",
"     2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.",
"     <br>",
"      3 = A condition for which the theoretical or proven risks usually outweigh the advantages of",
"      <br>",
"       &nbsp;using the method.",
"       <br>",
"        4 = A condition that represents an unacceptable health risk if the contraceptive method is used.",
"        <div class=\"footnotes\">",
"         STI: sexually transmitted infection; HIV: human immunodeficiency virus; ECP: emergency contraceptive pill; IUD: intrauterine device; COC: combined oral contraceptive; POP: progestin-only pill; CHC: combined hormonal contraceptive; POC: progestin-only contraceptive.",
"         <br/>",
"         * ECPs do not protect against STI/HIV. If risk exists for STI/HIV (including during pregnancy or postpartum), the correct and consistent use of condoms is recommended, either alone or with another contraceptive method. Consistent and correct use of the male latex condom reduces the risk for STIs and HIV transmission.",
"         <br/>",
"         <span class=\"bullet\">",
"          &bull;",
"         </span>",
"         Condition that exposes a woman to increased risk as a result of unintended pregnancy.",
"        </div>",
"        <div class=\"reference\">",
"         Reproduced from: Centers for Disease Control and Prevention (CDC). U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep 2010; 59:1.",
"        </div>",
"       </br>",
"      </br>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_22_3438=[""].join("\n");
var outline_f3_22_3438=null;
var title_f3_22_3439="Cervical flexion deformity AS";
var content_f3_22_3439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62964&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cervical flexion deformity in ankylosing spondylitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 194px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The severity of cervical flexion deformity in ankylosing spondylitis can be assessed by measuring the occiput to wall distance (Flesche test). With the patient standing erect, the heels and the buttocks are placed against a wall. The patient is then instructed to extend his or her neck maximally in an attempt to touch the wall with the occiput. The distance between the occiput and the wall is a measure of the degree of flexion deformity of the cervical spine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Craig W Wiesenhutter, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_22_3439=[""].join("\n");
var outline_f3_22_3439=null;
